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      Most newly synthesized messenger RNAs possess a 5’ cap and a 3’ poly(A) tail. The process of 
poly(A) tail shortening, also termed deadenylation, is important for post-transcriptional gene regulation, 
because deadenylation not only leads to mRNA translational inhibition but also is the first step of major 
mRNA degradation. Translationally inhibited mRNAs can be stored and/or degraded in dynamic 
cytoplasmic foci termed mRNA processing bodies, or P bodies, which are conserved in eukaryotes.   
       To shed new light on the mechanisms of P body formation and P body functions, I focused on the 
link between deadenylation factors and P bodies. I found that the two major deadenylation complexes, 
Pan3-Pan2 and Ccr4-Caf1, can both be enriched in P bodies. The deadenylase activity of the Ccr4-Caf1 
complex is prerequisite for P body formation. Pan3, but not the deadenylase Pan2, is essential for P 
body formation. While the C-terminal domain of Pan3 is important for interaction with Pan2, Pan3 N-
terminal domain is important for Pan3 to form cytoplasmic foci colocalizing with P bodies and to 
promote mRNA decay. Interestingly, Pan3 N-terminal domain may be phosphorylated to regulate Pan3 
localization and functions.  Aside from the functions of the two deadenylation complexes in P bodies, I 
also studied all reported human P body proteins as a whole using bioinformatics. This effort not only 
has generated a comprehensive picture of the functions of and interactions among human P body 
proteins, but also has predicted proteins that may regulate P body formation and/or functions.  
      In summary, my study has established a direct link between mRNA deadenylation and P body 
formation and has also led to new hypotheses to guide future research on how P body dynamics are 
controlled.    
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1.1 The Importance of Eukaryotic mRNA Poly(A) Tail 
 
      In eukaryotic cells, newly synthesized nuclear messenger RNAs generally possess a 5’ 7-
methylguanosine cap (m7G cap) and a 3’ polymer of adenosine-5’-monophosphate (poly(A) tail). The 
poly(A) tail was added to the pre-mRNA by a large cleavage/polyadenylation machinery via a two-step 
reaction. In metazoan cells, the first step is cleavage of the pre-mRNA between an A(A/U)UAAA 
hexamer and a U/GU-rich region. After cleavage, the poly(A) polymerase sequentially adds 100-250 
adenosine residues to the 3’ end of the cleavage product (1). The poly(A) tail is essential for both 
translation initiation and mRNA stability after the nascent transcripts are exported to the cytoplasm.    
1.1.1 Poly(A) tail in mRNA translation initiation 
 
      Translation of most eukaryotic mRNAs is initiated in a cap-dependent manner, which requires 
several eukaryotic initiation factors (eIFs). The cap binding protein eIF4E interacts with eIF4G, which 
recruits the 43S pre-initiation complex (2), consisting of the ternary complex eIF2-Met-tRNA-GTP, the 
40S ribosome subunit, and several initiation factors including eIF3 (3). The recruited 43S pre-initiation 
complex scans the 5’ untranslated region (UTR) of the mRNA in a 5’ to 3’ direction, until the start 
codon is recognized by the Met-tRNA, which eventually leads to the joining of the 60S ribosome 
subunit and formation of the 80S initiation complex ready for translation elongation (4).   
      By simultaneously interacting with the poly(A) binding protein (PABP) and the cap binding protein 
eIF4E, the scaffold protein eIF4G physically links the 3’ poly(A) tail and the 5’ cap (5) (Fig. 1.1). The 
circularization of mRNA through the cooperative interactions between PABP, eIF4G, and eIF4E 
enhances the RNA helicase activity of translation initiation factors eIF4A, eIF4B, and eIF-iso4F (6), 
resulting in increased translation initiation.  Moreover, the circularization of mRNA may enhance the 
recycling of ribosomes from the 3’ end to the 5’ end of the same mRNA, a notion further supported by 
the observation of interaction between the eukaryotic release factor 3 (eRF3) and PABP (7). The 
importance of poly(A) tail in cap-dependent translation initiation is exemplified during oocyte 
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maturation and early embryogenesis, during which the short poly(A) tails of a set of cytoplasmic 
mRNAs are elongated by cytoplasmic poly(A) polymerase. The polyadenylation transforms the mRNAs 
from translationally silent to active (8). A microarray analysis following separation of cellular mRNAs 
according to their poly(A) tail length indicated that yeast mRNA poly(A) tail length positively correlates 
with ribosome density (ribosomes per unit length of mRNA), further confirming the importance of 
poly(A) tail in translation (9).  
 
 
Figure 1.1: The closed-loop model. eIF4G interacts with both the cap binding protein eIF4E and the 
poly(A) tail binding protein PABP to circularize the mRNA and promote translation initiation. 
 
      Translation of some viral and about 10-15% of eukaryotic mRNAs can also be initiated in a cap-
independent manner (10, 11) through direct recruitment of the 40S ribosome subunit by internal 
ribosome entry sites (IRES), which are highly structured regions within the 5’ UTR. IRES-mediated 
translation initiation is generally not affected by conditions that inhibit cap-dependent translation 
initiation, thus allowing the cells to cope with some stressful situations (3). Surprisingly, IRES-mediated 
translation initiation of the c-myc and BiP mRNAs is also enhanced by the poly(A) tail, although PABP 
and eIF4G are not involved (12, 13).   
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1.1.2 Poly(A) tail in mRNA stability 
 
      The poly(A) tail not only enhances translation initiation, but also stabilizes eukaryotic mRNAs in 
the cytoplasm. The importance of poly(A) tail in stabilizing mRNAs is reflected by the fact that 
shortening of the poly(A) tail (deadenylation) is a prerequisite for the subsequent degradation of most 
cytoplasmic mRNAs, regardless of whether they are degraded by the exosome complex from 3’ to 5’or 
by the 5’ to 3’ exonuclease Xrn1 following decapping (14, 15) (Fig. 1.2). In mammalian cells 
deadenylation is the first step of the decay of both stable messages, such as beta-globin mRNA (16), and 
unstable messages, such as mRNAs bearing premature termination codons (PTC) (16), AU-rich 
elements (AREs) (17, 18), or miRNA targeting sites (19, 20). Consistently, blocking deadenylation by 
knocking down the enzymes catalyzing the deadenylation process (deadenylases) or by over expression 
of catalytically inactive deadenylase mutants stabilized mRNAs in mammalian cells (16, 21).    
 
Figure 1.2: Deadenylation is the first step for the degradation of most cytoplasmic mRNAs. After 
deadenylation, mRNAs can be degraded in two pathways. In one pathway, the mRNAs are decapped 
and then degraded from 5’ to 3’ by Xrn1. In the other pathway, the mRNAs are degraded from 3’ to 5’ 
by the exosome complex, followed by Dcps-mediated decapping. 
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      Why is the poly(A) tail so important for mRNA stability? The poly(A) tail and the associated 
cytoplasmic PABP may inhibit the 3’ to 5’ mRNA decay pathway simply by blocking the access of 
exosome to the mRNA. On the other hand, the 5’ to 3’ mRNA decay pathway can be inhibited by the 
poly(A) tail and associated PABP through several mechanisms. For example, in rabbit reticulocyte 
lysates, the cooperative interactions between PABPC, eIF4G, and eIF4E significantly strengthened the 
interaction between the 5’cap and eIF4E (22), which protects the 5’ cap from the decapping machinery. 
PABP can also directly bind to 5’ end of capped mRNA (23), which may help to inhibit decapping as 
well. In addition, the poly(A) tail and PABP can inhibit the recruitment of decapping activators such as 
the Lsm1-7p complex in yeast (24). 
1.2 Major Eukaryotic Deadenylases 
 
      The mRNA poly(A) tail can be shortened from 3’ to 5’ by deadenylases in the cytoplasm. Two 
deadenylase complexes highly conserved in yeast and human are the PAN and Ccr4-Not complexes. 
Other deadenylases, such as PARN and Nocturnin, only exist in higher eukaryotes (25). In the following 
section, these deadenylases will be briefly reviewed. 
      The PAB-dependent poly(A)-specific ribonuclease (PAN) is a heterodimer composed of the Pan3 
and Pan2 subunits. Pan2 is a Mg2+-dependent exoribonuclease that releases 5′-AMP from the 3′ end 
of poly(A) tails (26, 27). Sequence analysis using Conserved Domain Database (28) showed that Pan2 
contains an exonuclease domain, a peptidase domain, and a WD40 domain. The exonuclease domain is 
related to the DEDD superfamily and contains four conserved acidic residues that bind the Mg2+ ion 
involved in catalysis (29). Pan3 can interact with both Pan2 and PABP (Pab1p in yeast) to recruit Pan2 
to the poly(A) tail. In addition, in vitro experiments further showed that PAN is activated by PABP 
associated with the RNA substrates (27, 30). Interestingly, the 3’ UTR of yeast MFA2 RNA can also 
stimulate the activity of PAN, suggesting that PAN activity is not solely regulated by PABP (26). 
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      In yeast, Pan3p-Pan2p slowly shortens mRNA poly(A) tails when the major deadenylase Ccr4p-
Pop2p (yeast Caf1p) is deleted (31). Yeast strains harboring deficient Pan2p, Pan3p, or Pab1p (yeast 
homolog of PABP), produce mRNAs with longer poly(A) tails (30, 32, 33). In mammalian cells, the 
Pan3-Pan2 complex carries out the first phase of deadenylation in the cytoplasm by shortening mRNA 
tails from over 200 nt to about 110 nt before the Ccr4-Caf1 deadenylase takes over in the second phase 
of deadenylation (16, 19). Pan3 can be phosphorylated (34), but how Pan3 phosphorylation affects its 
localization and functions has never been studied.  
      Yeast Pan3p-Pan2p complex may also play a role in controlling the poly(A) tail length of newly 
synthesized mRNAs. It has been reported that partially purified RNA 3′-end processing machinery 
from yeast Pan3∆, Pan2∆, or Pan3∆Pan2∆ strains produced transcripts with poly(A) tails longer than 
those from a wild-type yeast (35). Within 10 min after addition of purified Pab1p and Pan3p-Pan2p, the 
long tails were trimmed to 60-80 residues, a length normally observed in the wild-type extract. The 
poly(A) tails were then only slowly shortened over the next 20 min in the reaction. Additionally, in vivo 
transcriptional pulse chase experiments showed that the first population of PGK1 transcripts generated 
after 4 minutes of galactose-mediated transcription had already undergone Pan3-Pan2 specific 
processing, indicating that Pan3p-Pan2p mediated rapid trimming of newly synthesized poly(A) tails in 
vivo. Thus, it was proposed that cleaved pre-mRNAs are polyadenylated to a long default length by the 
poly(A) polymerase machinery and then quickly deadenylated to a message-specific length by Pan3p-
Pan2p in a Pab1-dependent manner (35). However, this model was challenged by a recent observation 
that the poly(A) tail length control of the CYC1 mRNA in an in vitro system was restored by adding the 
nuclear poly(A)-binding protein Nab2p even in the absence of Pan3p and Pan2p (36).     
      In eukaryotes, the major deadenylase activity is carried by the CCR4-NOT complex which contains 
the deadenylases Ccr4 and Caf1 and several different NOT (negative regulator of transcription) proteins 
(37, 38). Ccr4 contains a leucine-rich repeat (LLR) responsible for interaction with Caf1 (39) and a 
ribonuclease domain similar to a family of Mg2+-dependent nucleases related to E. coli exonuclease III. 
Yeast Ccr4p exhibited poly(A)-specific 3′ exoribonucleases activity in vitro even in the absence of the 
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other subunits of the CCR4-NOT complex (40). Deletion of the CCR4 gene in yeast slowed down the 
rate of deadenylation and stabilized mRNAs (31).Unlike the Pan3p-Pan2p complex, the in vitro activity 
of yeast Ccr4p can be inhibited by Pab1p (38). 
      Although Ccr4p is the major deadenylase in the Ccr4-Not complexes in yeast (38), Caf1p (Pop2p) is 
also required for efficient mRNA degradation in vivo and has weak deadenylase activity in vitro (41, 
42). Like Pan2, Caf1 is a member of the DEDD family of exoribonucleases (43). Human Caf1 has two 
paralogs, CNOT7 (hCaf1/Caf1a) and CNOT8 (hPop2/Caf1b), both of which are catalytically active and 
required for efficient proliferation of cultured cells (44). 
      In addition to Ccr4p and Caf1p, the 1-MDa yeast CCR4-NOT complex contains the five NOT 
proteins (Not1-5p) as well as Caf40p and Caf130p (45). Deletion of some of the NOT genes in yeast  
negatively affected reporter mRNA deadenylation(38). A microarray analysis of mRNAs from yeast 
strains with deletion of individual subunits of the Ccr4-Not complex showed that each of the subunits 
regulates the expression of a specific group of genes (46). In Drosophila Schneider cells, siRNA-
mediated silencing of CAF1, NOT1, NOT2, and NOT3, but not CCR4, CAF40, or NOT4, inhibited bulk 
deadenylation (47). Interestingly, a yeast decapping factor, Dhh1p, co-immunoprecipitates with Not1p, 
suggesting a physical link between deadenylation and decapping machineries (48). (38) 
      The Ccr4-Not complex can be recruited to specific mRNAs to promote deadenylation of the mRNAs. 
TOB, a member of the anti-proliferative BTG (B-cell translocation gene) family, interacts with both 
PABP and human Ccr4-Not complex to promote mRNA deadenylation (49). TOB -/- and CNOT7(Caf1) 
-/- mice both exhibit increased bone formation (50, 51), suggesting that TOB may recruit the Ccr4-Not 
complex to promote the decay of transcripts of genes involved in bone formation. Yeast Vts1p, a 
sequence-specific RNA binding protein, interacts with and recruit the Ccr4-Not complex, resulting in 
deadenylation of the target mRNAs (52). In mammalian cells, the Ccr4-Not complex also mediates 
deadenylation of miRNA targets (19) and mRNAs bearing premature termination codon (PTC) or AU-
rich elements (AREs) (21).   
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      PARN, another member of the DEDD nuclease family, is a Mg2+-dependent poly(A)-specific 3’ 
exoribonuclease inhibited by PABP (53, 54). PARN contains an RNA-binding domain and can bind 
both the 5’ cap and the poly(A) tail of mRNAs (55, 56). Interestingly, cap binding enhances the activity 
and processivity of PARN (55, 57).  Although not found in yeast, PARN is indispensable for 
embryogenesis in higher plants and promotes deadenylation of a subset of embryo-specific mRNAs (58). 
Some studies, mostly using in vitro decay systems, suggested that mammalian PARN was recruited by 
several ARE binding proteins to promote deadenylation of transcripts containing AREs (59-61). 
However, direct in vivo evidence showed that unlike Pan2 and Ccr4, PARN did not play a major role in 
general deadenylation in mouse NIH 3T3 cells (16).  
      Nocturnin, a deadenylase related to Ccr4, is unique in that it is encoded by a clock-controlled gene 
whose transcription peaks at night in Xenopus retinal phosphoreceptor cells (62) and multiple tissues of 
mice (63). Interestingly, Nocturnin knockout mice have defects in lipid metabolism and are therefore 
immune to diet-induced obesity and hepatic steatosis(64).   
      In summary, different deadenylases may function in unique ways, which may be overlapping 
sometimes, to shorten mRNA poly(A) tails, leading to translational inhibition and/or degradation of the 
mRNAs.    
1.3 mRNA Processing Bodies 
 
      mRNA processing bodies, also named P bodies or GW bodies, are dynamic cytoplasmic aggregates 
of non-translating mRNAs and factors involved in mRNA translational inhibition and decay. Conserved 
from yeast to human, P bodies have a diameter of 100-300 nm (65). These membrane-free structures are 
mainly anchored to microtubules while constantly moving around in the cytoplasm (66).  
      Under light microscope, P bodies co-localize with translationally inhibited mRNAs and around 30 or 
50 different proteins in yeast and human cells, respectively. These P body proteins are either involved in 
mRNA binding (e.g. eIF4E), translational inhibition (e.g. eIF4ET and CPEB1), mRNA decapping (e.g. 
Dcp1/2 and Lsm1-7), mRNA 5’ to 3’ degradation (e.g. Xrn1), miRNA-mediated gene silencing (e.g. 
Ago1-4 and GW182), or with unknown functions (e.g. ZAR1l) (67, 68). Factors involved in nonsense-
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mediated decay (NMD) were enriched in P bodies when NMD is interrupted in yeast (69) and in 
mammalian cells (70). In contrast, most factors involved in mRNA translation, for example PABP, 
eIF4G, and ribosome subunits, are normally absent from P bodies (71).  
      P bodies are sites for mRNA translational inhibition, degradation, and storage (Fig. 1.3). Because P 
bodies are ribosome-free, mRNAs in P bodies cannot be translated. Some mRNAs are likely degraded 
in P bodies, as inhibition of 5’ to 3’ decay by knocking down Xrn1 increased P body sizes and mRNA 
decay intermediates were found in P bodies (72). However, P bodies may also be temporary storage 
sites for some mRNAs, as suggested by an observation that a P body mRNA encoding cationic amino 
acid transporter 1 (CAT-1) was released from P bodies and subsequently translated when the cells were 
subjected to different stresses (73). Therefore, P bodies may function as a “lockup” where the fates of 
arrested non-translating mRNAs will be determined.  
      Although P bodies are conserved in eukaryotes, the physiological significance of their formation is 
unknown. One possibility is that by enriching local concentrations of translational inhibitors and mRNA 
decay factors, cells can silence unwanted mRNAs more effectively. 
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Figure 1.3: Translationally inhibited mRNAs in P bodies can be degraded or released back to the 
cytosol for translation. Translation factors such as PABP, eIF4G, and ribosome subunits are released 
from mRNAs targeted to P bodies, where these mRNAs can be decapped by Dcp1/2 and degraded from 
5’ to 3’ by Xrn1. However, mRNAs in P bodies may also be released to the cytosol and translated. 
          
      P body formation involves remodeling and subsequent aggregation of mRNAs and their associated 
proteins, together known as messenger ribonucleoproteins (mRNPs). The mRNP remodeling may 
include recruitment of translational inhibitors and dissociation of translation activators and translation 
machinery. siRNA-mediated knockdown of translational inhibitors such as eIF4E-T and RCK/p54 
blocked P body formation (74, 75). Cycloheximide treatment, which inhibits the release of ribosomes 
from mRNAs, also abolished P body formation (72, 76). Since deadenylation often leads to mRNA 
translational inhibition and mRNA degradation, it is likely that deadenylation is required for P body 
formation. In Hela cells, siRNA-mediated knockdown of Ccr4 blocked P body formation (74). 
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Surprisingly, deletion of Ccr4 or Pop2(Caf1), the major deadenylases in yeast, only slightly reduced P 
body formation (77). However, it is unclear whether deadenylation was completely inhibited by Ccr4 
knockdown. The localization and functions of the Pan3-Pan2 complex and Caf1 with regards to P 
bodies had not been reported. Therefore the role of deadenylases in P body formation or functions 
remained elusive.  
      The aggregation of the translationally inhibited mRNPs into microscopically visible P bodies seems 
to depend on protein-protein interactions, a notion supported by the discovery that most yeast P body 
components contain Q/N-rich aggregation-prone regions (78). However, it is not known if the Q/N-rich 
regions are also enriched in mammalian P body components.  
      Although hundreds of studies of P body components have been published, a comprehensive list of 
reported P body proteins is lacking, hampering the studying of P bodies as a whole. A comprehensive 
list of P body proteins will allow us to predict new P body proteins in mammalian cells, envision how 
some of the P body components may function together in the same pathways or processes, and analyze 
how P body proteins interact with each other and with other cellular proteins.  Thus, such list will lead 
to a better understanding of the physiological significance of P-bodies and how P body dynamics may 
be controlled.      
         
1.4 Significance of my study 
 
      The first part of my study, as described in Chapter 2, was focused on the localization of 
deadenylases with regards to P bodies and their functions in P body formation. This study has shed new 
light on the mechanisms of P body formation by showing that 1) deadenylase activity of the Ccr4-Caf1 
complex is required for mammalian P body formation, and 2) Pan3 is required for P body formation. 
      The focus of Chapter 3 is functional dissection of Pan3 domains and to test the possible role of Pan3 
phosphorylation. This study not only helped us further understand the functions of Pan3 in both 
deadenylation and P body formation but also suggested that Pan3 localization and functions might be 
regulated by phosphorylation.   
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       Chapter 4 is a bioinformatics study of all reported P body components, which not only provides a 
comprehensive picture of P body organizations and potential functions but also predicts new factors 
important for P body dynamics and functions.     
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Chapter 2: Deadenylation is Required 
for mRNA Processing Body Formation 
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2.1. Introduction 
 
      Shortening of mRNA poly(A) tails, a process termed deadenylation, is essential for post-
transcriptional inhibition of gene expression in eukaryotes, because the poly(A) tail significantly 
enhances cytoplasmic mRNA stability and translation initiation. The importance of poly(A) tail in 
stabilizing mRNAs is reflected by the fact that deadenylation is the first step for the decay of both stable 
and many unstable messages (16-20). The poly(A) tail also enhances translation through the poly(A) 
binding protein (PABP) and eIF4G-mediated mRNA circularization, which may facilitate the recycling 
of ribosomes from the 3’ end to the 5’ end of the same mRNA (7, 79) and may also enhance the RNA 
helicase activity of some translation initiation factors (6).   
      Deadenylation is catalyzed by deadenylases, such as the highly conserved eukaryotic Pan3-Pan2 and 
Ccr4-Caf1 complexes. In the Pan3-Pan2 complex, Pan2 catalyzes deadenylation while Pan3 can interact 
with both Pan2 and the PABP to regulate Pan2 activity (27, 30). On the other hand, both Ccr4 and Caf1 
have deadenylase activities (37, 38, 42). In yeast, the Ccr4p-Caf1p complex is responsible for major 
deadenylation in the cytoplasm (31). In vitro study showed that the deadenylase activity of Ccr4-Caf1 
complex is inhibited by PABP (38). In mammalian cells, deadenylation in the cytoplasm are biphasic. 
Poly(A) tails are first shortened to about 110 nt by the Pan3-Pan2 complex, followed by a second phase 
of deadenylation, during which the Ccr4-Caf1 complex catalyzes further shortening of the poly(A) tail 
to oligo(A) (16).  
      After deadenylation, the mRNA can either be degraded in a 3’ to 5’ direction by the exosome 
complex or be decayed from 5’ to 3’ by Xrn1 following decapping by Dcp1-Dcp2 decapping complex 
(80). Translationally inhibited mRNAs, translation inhibitors, decapping factors, and the 5’ to 3’ 
riboexonuclease Xrn1 are found in cytoplasmic foci named mRNA processing bodies or P bodies, 
which are membrane-free mRNP aggregates with a diameter of 100-300 nm (65).   
      P bodies are sites for mRNA translational inhibition, degradation, and storage. Because P bodies are 
ribosome-free, mRNAs in P bodies cannot be translated (71). P body mRNAs can be degraded, as 
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inhibition of 5’ to 3’ decay by knocking down Xrn1 increased P body sizes and mRNA decay 
intermediates were found in P bodies (72). P bodies may also be temporary storage sites for some 
mRNAs before they are degraded, as suggested by an observation that an P body mRNA encoding 
cationic amino acid transporter 1 (CAT-1) was released from P bodies and subsequently translated when 
the cells were subjected to different stresses (73). Therefore, P bodies provide a location where the fates 
of non-translating mRNAs (either degradation or release) will be determined pending on the condition.  
      While decapping and 5’ to 3’ mRNA decay can impact P body formation, the link between 
deadenylation and P bodies is unclear. In yeast, both Ccr4p and Pop2p (yeast Caf1) only co-localize 
with P bodies in strains where decapping or 5’ to 3’ mRNA decay is inhibited (77). GFP-tagged human 
Ccr4 can weakly localize to P bodies in HEK293 cells (76). The Pan3-Pan2 complex was reported to 
localize in the cytoplasm in both yeast and mammalian cells (16, 27); however, it was unknown whether 
the Pan3-Pan2 deadenylase complex can be found in P bodies. 
      Deadenylation might be one of the mRNP remodeling steps required for P body formation because it 
results in mRNA translational inhibition and mRNA decay, both of which can occur in P bodies. The 
observation that siRNA-mediated knockdown of Ccr4 blocked P body formation in Hela cells (74) 
supports this notion. However, it remains to be determined whether the deadenylase activity or the 
structural entity of Ccr4 is required for P body formation. Besides, deletion of either Ccr4p or Pop2p 
(yeast Caf1) only had a small effect on P bodies in yeast (77). Therefore, it remains elusive, especially 
in mammalian cells, whether the deadenylase activities of the Ccr4-Caf1 and Pan3-Pan2 complexes are 
required for P body formation.    
      To reveal the link between P body formation and deadenylation and shed new light on the 
mechanisms of eukaryotic post-transcriptional gene regulation, I examined cellular localizations of the 
Pan3-Pan2 and Ccr4-Caf1 complexes with regards to P bodies, the importance of deadenylase activity 
in P body formation, and the underlying mechanisms for the deadenylation-P body formation 
relationship in mammalian cells. These experiments revealed that the Pan3-Pan2 complex is enriched in 
mammalian P bodies and that Pan3 helps the Ccr4-Caf1 complex localize to P bodies. In addition, 
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combining in vivo functional analysis performed in our lab, we demonstrated that mammalian P body 
formation depends on the deadenylase activity of the Ccr4-Caf1 complex, even when mRNAs are 
rendered ribosome-free by puromycin treatment. Taken together, this study provides new insights into 
the mechanisms of P body formation and post-transcriptional gene regulation.  
 
2.2. Materials and Methods 
2.2.1. Plasmids 
      To construct a plasmid encoding HA-tagged Pan3 or Caf1, a 2.2-kb Pan3L cDNA amplified by RT-
PCR from human testis total RNA (Clontech Laboratories, Inc.) or an 855-bp fragment encoding Caf1 
amplified from IMAGE clone 6207987 was inserted between the EcoRV and XhoI sites of pSRHisHA 
(gift from S. Ohno, Yokohama City University, Yokohama, Japan). The Caf1 cDNA was inserted 
between the HindlII and XbaI sites of pcDNA6/V5-HisA (Invitrogen) to generate pcDNA6-Caf1-V5. A 
plasmid encoding catalytic inactive Caf1 mutant (D40A) was created using the QuikChange site-
directed mutagenesis kit (Stratagene) with pSR-HA-Caf1 as the template. To construct pcDNA6-Pan2-
V5, a 3.6-kb Pan2 cDNA was amplified from IMAGE clone 3357890 and inserted between the AflII 
and XbaI sites of pcDNA6/V5-HisA (Invitrogen). GFP-Dcp1a and GFP-Ccr4 (gifts from B. Seraphin, 
Centre de Génétique Moléculaire, Gif sur Yvette Cedex, France) were described previously (21). 
2.2.2. Cell culture and transfection 
 
      Either Lipofectamine 2000 (Invitrogen) or FuGENE 6 (Roche) was used for transient transfections. 
NIH3T3 B2A2 cells were split to a density of 2.6 × 106/10-cm dish 24 h before transfection in 100 
ng/ml tetracycline. 40 μl Lipofectamine 2000 and 1.5 ml Opti-MEM were mixed well and incubated 
for 5 min at RT. DNA (1.3 μg of reporter plasmid and 1.3 μg of internal control plasmid, pSV–α-
globin–GAPDH) and siRNA (4.86 μg of nonspecific siRNA or Pan3 siRNA, or 2.43 μg Caf1 siRNA 
plus 2.43 μg Pop2 siRNA [SMARTpool; Thermo Fisher Scientific]) were diluted into 1.5 ml Opti-
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MEM, added to the Lipofectamine 2000 mixture, and incubated at RT for 25 min. The final mixture was 
then added to the cells in a 10-cm dish and incubated at 37°C (5% CO2). Cells were split 18 h later into 
6-cm dishes (1.5 × 106/6 cm dish) and incubated at 37°C (8% CO2) for 24 h. When using FuGENE 6, 
NIH3T3 B2A2 cells were split to a density of 0.65 × 106/6-cm dish 24 h before transfection in the 
presence of 50 ng/ml tetracycline. 6.9 μl FuGENE 6 was diluted in 100 μl DME and mixed with 2.3 
μg DNA containing 0.055 μg of reporter plasmid, 0.11 μg of internal control plasmid, and 2.13 μg 
of DNA encoding HA-tagged proteins. The mixture was incubated at RT for 25 min, added to the 
culture dish, and incubated at 37°C (8% CO2) for 42 h. Time-course experiments using the Tet-off 
system for transcriptional pulsing were performed as described previously (21, 81). 
2.2.3. Western blot analysis  
 
      Cytoplasmic and nuclear lysates were prepared as described previously (82). Total cell lysates (5–40 
μg) were resolved on a 7 or 10% SDS-polyacrylamide gel and analyzed using an ECL Western blotting 
kit (GE Healthcare). The PVDF blots were probed with specific antibodies as indicated in each figure 
and detected with SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific). 
Membranes were incubated with one of the primary antibodies at the indicated dilution: HRP-
conjugated monoclonal Anti-V5 antibody at 1:5,000 (Invitrogen); HRP-conjugated monoclonal anti-HA 
antibody at 1:1,000 (Roche); rat anti-HA monoclonal antibody at 1:4,000 (Roche); mouse anti–α-
tubulin monoclonal antibody at 1:10,000 (Sigma-Aldrich); rabbit anti-Dcp1a serum at 1:4,000 (Bethyl 
Laboratories, Inc. or gift from S. Ohno); rabbit anti-Rck/p54 serum at 1:1,000 (Bethyl Laboratories, 
Inc.); mouse monoclonal antibody against GAPDH at 1:10,000 (Research Diagnostics, Inc.); and mouse 
antibody against lamin A/C at 1:1,000 (Santa Cruz Biotechnology, Inc.). Rabbit anti-PABP antibody 
(gift from R. Lloyd, Baylor College of Medicine, Houston, TX) was used at a 1:4,000 dilution. To 
detect endogenous Caf1, Pan2, and Pan3 in mouse NIH3T3 or monkey COS7 cells, the corresponding 
polyclonal antibodies were generated in rabbits immunized with gene-specific peptides using the custom 
antibody service from Bethyl Laboratories, Inc. Affinity-purified anti-peptide antibodies were used at 
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the following dilutions: rabbit anti-Pan3 peptide antibody at 1:2,000; rabbit anti-Caf1 peptide at 1:1,000; 
or rabbit anti-Pan2 peptide at 1:2,000. HRP-conjugated donkey anti–rabbit IgG antibodies (1:4,000; GE 
Healthcare) or goat anti–mouse (1:5,000; Bio-Rad Laboratories) were used as secondary antibodies for 
detection with a chemiluminescence reagent (peroxide/luminol enhancer; Thermo Fisher Scientific) (21). 
2.2.4. Immunofluorescence staining and microscopy 
 
     NIH3T3 cells were seeded in 6-well plates at a density of 0.4 × 106 cells per well, 24 h before 
transfection using Lipofectamine 2000 (Invitrogen). At 22–26 h after transfection, cells were reseeded 
to slide chambers (BD Biosciences) and incubated overnight. For cycloheximide, puromycin, or arsenite 
treatment, cells were incubated in media containing either 7.5 μg/ml cycloheximide (Sigma-Aldrich) 
for 2 h, 100 μg/ml puromycin (Sigma-Aldrich) for 1 h, or 0.3 mM sodium arsenite (Sigma-Aldrich) for 
1 h before fixation. Cells in the slide chambers were fixed for 10 min each with 3.7% (wt/vol) PFA 
(Sigma-Aldrich) in PBS and then with cold methanol, followed by a 10-min incubation in 0.2% (vol/vol) 
Triton X-100 in PBS. Each microgram of Zenon-labeled antibodies (see third paragraph in this section) 
was diluted in 500 μl of 1% BSA in PBS and incubated with the fixed slides. After incubating for 1 h 
at RT and washing, the slides were fixed again in 3.7% PFA. For indirect immunofluorescence 
microscopy, all of the primary and secondary antibodies, except the mouse anti-myc serum, were 
diluted 1:1,000 with 1% (wt/vol) BSA in PBS. Endogenous Pan2 was detected using rabbit anti-Pan2 
labeled with Zenon 555 rabbit IgG labeling reagent. Endogenous Dcp1a, Xrn1, or Pan3 was detected 
using rabbit anti-Dcp1a, anti-Xrn1, or anti-Pan3 labeled with Zenon 488 rabbit IgG labeling reagent. 
HA-tagged Pan3, Ccr4, or Caf1 was detected using rat anti-HA monoclonal antibody and Alexa Fluor 
350 goat anti–rat IgG. HA-Pan2 or V5-tagged proteins were detected using rat monoclonal anti-HA or 
mouse monoclonal anti-V5 and Alexa Flour 555 goat anti–rat IgG. Rabbit anti-Xrn1 antibody was a gift 
from J. Lykke-Andersen (University of Colorado at Boulder, Boulder, CO), human anti-GW182 
antiserum was a gift from M.J. Fritzler (University of Calgary, Calgary, Canada), rabbit anti-G3BP1 
was a gift from R. Lloyd (Baylor College of Medicine, Houston, Texas), and rabbit anti-Dcp1a antibody 
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was a gift from S. Ohno (Yokohama, Japan). The mouse anti-myc monoclonal antibody from culture 
medium collected from anti-myc monoclonal antibody secreting hybridoma cells (American Type 
Culture Collection) was used at 1:50 dilution. After incubation with the indicated primary 
antibodies/sera, cells were washed three times in PBS for 5 min and incubated with fluorescently 
labeled secondary antibodies (Invitrogen) as indicated in the figures. Fluorescence mounting medium 
with or without DAPI was added. 
      Images were obtained at RT by optical z-sectioning (20 sections in total, 0.2-μm-space between 
sections) using an objective lens (100×/1.35 NA; Olympus) of a deconvolution microscope system 
(DeltaVision) containing an inverted microscope (IX70; Olympus). Immersion oil (n = 1.514) was from 
Applied Precision, LLC. Images were captured using a digital camera (Coolsnap HQ; Roper Scientific). 
Stacks of 20 images were projected as a single 2D picture using softWoRx Explorer (version 3.3.6; 
Applied Precision, LLC). The RGB colors of the resulting pictures were separated using Photoshop CS 
(Adobe). 
      When two different primary antibodies raised in rabbits were used together to visualize P-bodies, the 
following procedure was used. One μg of rabbit antibody was incubated for 5 min at RT with 5 μl 
Zenon rabbit IgG labeling reagent, either Alexa Flour 488- or 555-labeled Fab fragment (Invitrogen). 
The labeled Fab fragment was bound to the Fc portion of the rabbit IgG, and excess Fab fragment was 
neutralized by the addition of 5 μl of nonspecific rabbit IgG, which prevented cross-labeling of the Fab 
fragment when two rabbit antibodies were used. After a 5-min incubation at RT, the labeled antibodies 
were used for staining in combination with each other or with labeled secondary antibodies specific for 
other species. To analyze the changes in P-body number and size after Pan3 knockdown, 87 cells 
transfected with control nonspecific siRNA and 91 cells transfected with Pan3 siRNA were analyzed 
using ImageJ software (pixel range for particle brightness between 40 and 215; National Institutes of 
Health). Dcp1a particles with values >50 square pixels were considered above background staining and 
were selected for P-body analysis (21). 
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2.3. Results 
2.3.1. Both Pan2 and Pan3 co-localize with P bodies in mammalian cells. 
 
      To reveal the link between deadenylation and P bodies, we first determined the subcellular 
localization of Pan2 and Pan3, the factors involved in initiating mammalian mRNA deadenylation (16), 
with regards to P-bodies in mammalian cells. The well-characterized P-body components Dcp1a and 
Xrn1 are used as markers to visualize P bodies by immune-fluorescence microscopy (83). The results 
show that cytoplasmic foci detected by an anti-Pan2 antibody co-localize with P bodies marked by 
endogenous Dcp1a (Fig. 2.1 A) in NIH 3T3 cells. Cycloheximide treatment, which blocks P body 
formation by inhibiting the release of ribosomes from mRNAs (84), also blocked Pan2 foci 
formation(Fig. 2.1 B). Endogenous Pan2 foci also co-localize with both endogenous Dcp1a foci and 
endogenous Xrn1 foci in COS7 cells (Fig. 2.1 C). These results indicate that Pan2 is a component of P 
bodies in mammalian cells.   
 Figure 2.1: Endogenous Pan2 is enriched in P bodies in both NIH 3T3 cells and COS7 cells.
(A) Immuno-fluorescence staining showing endogenous Pan2 colocalizes with Dcp1a
NIH 3T3 cells. (B) The Pan2 foci in NIH 3T3 cells are disassembled by cycloheximide treatment, as 
expected for P bodies. (C) Pan2 foci colocalize with P
Xrn1 (bottom) in COS7 cells. (
 
                                    Courtesy to
-bodies detected with anti-Dcp1a (top) or anti
The experiments were repeated once.)  
 The Journal of Cell Biology (21). 
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      Next we checked if Pan3, the other subunit of the Pan3-Pan2 complex, also co-localizes with P 
bodies. Due to the lack of an anti-Pan3 antibody suitable for immune-fluorescence microscopy, a 
plasmid encoding HA-tagged Pan3 (HA-Pan3) was delivered into NIH 3T3 cells through transient 
transfection and an anti-HA antibody was used to study the sub-cellular localization of HA-Pan3. As 
expected, HA-Pan3 also co-localizes with P bodies labeled with either anti-Dcp1a or GFP-Dcp1a in 
NIH 3T3 cells (Fig. 2.2 A). Since Pan3 can also interact with PABP (27, 30), which was not found in P 
bodies previously (71), we checked if PABP can be enriched in HA-Pan3 foci. We found that neither 
ectopically expressed myc-tagged PABP (Fig. 2.2 B) nor endogenous PABP (data not shown) is 
concentrated in HA-Pan3 foci. Moreover, the HA-Pan3 foci are not stress granules, as they do not co-
localize with the stress granule marker G3BP-1 (71), no matter whether the cells were treated with 
arsenite to induce stress granule formation (Fig. 2.2 C, top) or not (Fig. 2.2 C, bottom).  Collectively, 
our results identify both Pan2 and Pan3 as two new components of P bodies in mammalian cells. 
 
 Figure 2.2: PABP is not found in HA
granules.  (A) Immuno-fluorescence staining showing ectopically expressed HA
colocalizes with endogenous Dcp1a (top) and EGFP
cells. (B) HA-Pan3 foci do not colocalize with myc
stress granule marker G3BP-1 in NIH 3T3 cells with (top) or without (b
experiments were repeated at least once.)
-Pan3 foci, which coloclaize with P bodies but not stress 
-tagged Pan3 
-tagged Dcp1a (bottom) in P bodies of NIH 3T3 
-PABP. (C) HA-Pan3 foci do not colocalize with the 
ottom) arsenite treatment. 
   
Courtesy to The Journal of Cell Biology (21). 
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2.3.2. Pan3 is an essential P body component that can recruit the non-essential P body component 
Pan2 to P bodies    
 
      Since both Pan3 and Pan2 are P body components, we next determined whether they are essential 
for P body formation in NIH 3T3 cells. To this end, NIH 3T3 cells were transfected with either non-
specific siRNA (NS siRNA), Pan3 specific siRNAs, or Pan2 specific siRNA, followed by immuno-
fluorescence microscopy and particle analysis using the free NIH software ImageJ (85). siRNA-
mediated Pan3 knockdown in NIH 3T3 cells dramatically decreased the number and average size of P 
bodies in cells labeled with anti-RCK/p54, another popular P body marker (Fig. 2.3). This observation 
suggests that Pan3 is an essential component of P bodies. On the other hand, siRNA-mediated Pan2 
knockdown had little effect on P body formation (Fig. 2.4 A&B). Moreover, overexpression of a 
catalytic mutant of Pan2 did not block P body formation (Fig. 2.4 C). These observations suggest  that 
Pan2 is not essential for P body formation.   
          
 
 
 
 
 Figure 2.3: siRNA-mediated Pan3 knockdown inhibits P body formation in NIH 3T3 cells.
 
(A) Western Blotting showing knockdown of Pan3 by siRNA.  (
anti-RCK/p54 to detect P bodies in NIH 3T3 cells transfected with either Pan3 siRNA or nonspecific 
siRNA. (C) Analysis of P body numbers and average sizes in NIH 3T3 cells transfected with either 
Pan3 siRNA or nonspecific siRNA
 
B) Immuno-fluorescence staining using 
. The experiment was repeated once. 
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 Figure 2.4: siRNA-mediated Pan2 knockdown has little effect on P body formation in NIH 3T3 
cells. 
 
(A) Western Blotting showing knockdown of Pan2 by siRNA.  (
anti-RCK/p54 to detect P bodies in NIH 3T3 cells transfected with either Pan2 siRNA or nonspecific 
siRNA.(C) Overexpression of a catalytic mutant of Pan2 
experiment was repeated once.
 
C. 
B) Immuno-fluorescence staining using 
did not block P body formation. 
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      The above results are consistent with the following observations. Firstly, HA-Pan3 localizes to P 
bodies when it is ectopically expressed alone (Fig. 2.2 A), suggesting that Pan3 can associate with P 
bodies without a coordinated expression of Pan2. Secondly, ectopically expressed Pan2 did not form 
any cytoplasmic foci when expressed alone (Fig. 2.5 A), but did co-localize with P bodies when co-
expressed with HA-Pan3 (Fig. 2.5 B), indicating that Pan2 is recruited to P bodies through its 
interaction with Pan3. Together, these results indicate that Pan3 is an essential P body component that 
can recruit the non-essential P body component Pan2 to P bodies.   
 
 
 
 
 
 
 
 
 
 Figure 2.5: HA-Pan3 helps ectopically expressed Pan2 to colocalize with P bodies. 
 
(A) Ectopically expressed HA-
enriched in P bodies.  (B) V5-tagged Pan2 is enriched in P bodies when HA
co-expressed. The experiment was repeated twice.
 
 
 
 
 
 
tagged Pan2 (top) and V5-tagged Pan2 (bottom) can
-tagged Pan3 is 
 
Courtesy to The Journal of Cell Biology (21). 
. 
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2.3.3. HA-Pan3 helps co-expressed Caf1 and Ccr4 to be enriched in P bodies.  
 
      After the first phase of deadenylation by the Pan3-Pan2 complex, the Ccr4-Caf1 deadenylase 
complex catalyzes the second phase of deadenylation (16). Since Ccr4 weakly localize to P bodies in 
HEK293 cells (76), we asked whether Caf1, which forms a complex with Ccr4, also co-localizes with P 
bodies. Our results show that ectopically expressed Caf1 was not enriched in P bodies in NIH 3T3 cells, 
regardless of whether it was expressed alone (Fig. 2.6 A, top) or together with ectopic Ccr4 (Fig. 2.6 A, 
bottom). GFP-tagged Ccr4 also did not form any foci co-localizing with P bodies in NIH 3T3 cells (Fig 
2.6 C). Our results are consistent with the observations that yeast Ccr4p and Caf1p (Pop2p) normally do 
not co-localize with P bodies (77). Because the Pan3-Pan2 complex, which catalyzes the first phase of 
deadenylation, is in P bodies, we suspected that co-expressed HA-Pan3 can help the second phase 
deadenylases Ccr4 and Caf1 to localize to P bodies. Indeed, both V5-tagged Caf1 and GFP-tagged Ccr4 
were enriched in P bodies when HA-Pan3 was co-expressed (Fig. 2.6 B and D). The effect of co-
expressed HA-Pan3 on Caf1-V5 and GFP-Ccr4 localizations is not likely due to non-specific 
recruitment of co-expressed proteins by HA-Pan3 foci, because co-expressed myc-PABP was not 
enriched in HA-Pan3 foci (Fig 2.2 B).       
 Figure 2.6: HA-Pan3 helps ectopically expressed Caf1 and Ccr4 to colocalize with P bodies.
   
(A) Ectopically expressed V5-tagged Caf1 (top) can
tagged Ccr4 is co-expressed (bottom). (
tagged Pan3 is co-expressed. (C
cells. (D) GFP-Ccr4 can be enriched in P bodies when co
experiment was repeated twice.
not be enriched in P bodies, even when HA
B) V5-tagged Caf1 is enriched in P bodies when HA
) GFP-tagged Ccr4 can hardly be enriched in P bodies in NIH 3T3 
-expressed with HA-tagged Pan3.
 
Courtesy to The Journal of Cell Biology (21). 
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2.3.4. Deadenylase activity of the Ccr4-Caf1 complex is required for P body formation 
 
      Both Caf1 and Ccr4 can be enriched in P bodies when co-expressed with HA-Pan3. Since siRNA-
mediated knockdown of Pan3 inhibited P body formation in NIH3T3 cells (21) and Ccr4 knockdown 
was reported to block P body formation in Hela cells (74), we asked if Caf1 is also required for P body 
formation. siRNA-mediated Caf1 knockdown blocked P body formation (Fig 2.7), indicating that Caf1 
is important for the formation of microscopically visible P bodies.  
Next, we asked if the deadenylase activity of the Ccr4-Caf1 complex is required for P body formation. 
To this end, we created a catalytically inactive mutant of Caf1 by changing a critical aspartate residue 
necessary for metal binding and Caf1 nuclease activity to alanine by site-directed mutagenesis (29). 
While ectopically expressed wild-type Caf1 promoted deadenylation and subsequent decay of the 
reporter BBB mRNA (Fig. 2.8 C), mutant Caf1 expression almost completely blocked reporter mRNA 
deadenylation (Fig. 2.8 D). The reporter mRNA was still degraded, although at a much slower rate, 
suggesting that mRNA can be degraded in deadenylation-independent manner when deadenylation is 
blocked. The catalytically mutant, but not the wild-type, Caf1 also blocked P body formation in NIH 
3T3 cells (Fig. 2.8 E and F) and COS7 cells (data not shown). Interestingly, co-expression of wild-type 
Ccr4, but not catalyticaly mutant Ccr4, with Caf1 mutant restored fast deadenylation of the BBB 
reporter mRNA (Fig. 2.9 B), suggesting that the deadenylase activity of Ccr4 is complementary to Caf1 
in the Ccr4-Caf1 complex. Concomitantly, co-expressed wild-type Ccr4, but not catalytically mutant 
Ccr4, released the blockage of P body formation by Caf1mt (Fig. 2.9 D and E).  Collectively, our 
observations provided strong evidence that the deadenylase activity of the Ccr4-Caf1 complex is 
required for P body formation.     
 
 
 
  
Figure 2.7: siRNA-mediated Caf1 knockdown blocks P body formation in NIH 3T3 
 
(A) Western showing the knockdown of Caf1 by siRNA. 
effect of siRNA-mediated Caf1 knockdown on P body formation. 
times. 
 (B) Immuno-fluoresence staining showing the 
The experiments
 
Courtesy to The Journal of Cell Biology (21). 
. 
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cells.  
 were repeated three 
 Figure 2.8: Overexpressed Caf1 catalytic mutant, but not wild
formation and deadenylation.  
 
(A) Western showing the expression of HA
the effects of overxpression of nothing (
decay of the BBB reporter mRNA. (
HA-tagged Caf1 (E) or Caf1 catalytic mutant (
twice. 
 
Northern analysis (B,C,D) was performed by Wenmiao Zhu.
 
-type Caf1, inhibits both P body 
 
-tagged Caf1 and Caf1 mutant. (B-D) Northern blots howing 
B), wild-type (C), or mutant  (D) Caf1 on the deadenylation and 
E-F) Immuno-fluoresence staining showing ectopically expressed 
F) on P body formation. The experiment was repeated 
Courtesy to The Journal of Cell Biology (21).  
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 Figure 2.9: P body formation is restored when the blockage of deadenylation is released by co
expressed Ccr4.   
 
(A) Western blotting showing the expression of Caf1 
blots showing the effects of overxpression of both Caf1 mutant and wild
mutant (C) on the deadenylation and decay of the BBB reporter mRNA. (
staining showing ectopically expressed Caf1 catalytic mutant and wild
Ccr4 (E) on P body formation. 
Northern blot analysis (B) and (C) was performed by Wenmiao Zhu and Dr. Nader Ezzeddine, 
mutant and Ccr4 or Ccr4 mutant.  
-type Ccr4 (
D-E) Immuno
-type (D) or catalytically mutant 
The experiment was repeated twice. 
 
Courtesy to The Journal of Cell Biology (21).  
respectively. 
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2.3.5. Requirement of deadenylation for P body formation cannot be bypassed by puromycin 
treatment that removes ribosomes from mRNAs 
 
      Why is P body formation deadenylation-dependent? Since only ribosome-free mRNAs can enter P 
bodies and translation of most mRNAs is inhibited by deadenylation (9), it is likely that the requirement 
of deadenylation for P body formation is simply because deadenylation helps the mRNAs to become 
ribosome-free. To test this idea, puromycin was used to release ribosomes from cellular mRNAs (86) 
while deadenylation was inhibited either by overexpression of Caf1 catalytic mutant or siRNA-mediated 
knockdown of Caf1 in NIH 3T3 cells. Strikingly, puromycin treatment failed to induce P-body 
formation when deadenylation is inhibited (Fig 2.10), although puromycin indeed promoted P body 
formation in cells where deadenylation is not impaired. Therefore, deadenylation is required for mRNAs 
to enter P bodies even if the mRNAs are ribosome-free. In other words, the shortening of poly(A) tails 
per se, not only the release of ribosomes from mRNA, is one of the necessary remodeling steps for 
mRNPs to form P bodies.   
 Figure 2.10: Puromycin treatment cannot induce P body formation when HA
expressed or Caf1 is knocked down by siRNAs.  
 (A) Indirect immuno-fluorescence staining showing the effects of puromycin treatment on 
untransfected cells and cells expressing either wild
panel) Caf1. (B) Western blotting showing siRNA
fluorescence staining showing the effects of puromycin treat
knockdown on P body formation detected by GW182 antibody.
Courtesy to 
-
 
-type (upper panel) or catalytically mutant (lower 
-mediated Caf1 knockdown. (C) Indirect immuno
ment and/or siRNA-mediated Caf1 
 The experiment was repeated twice.
 
The Journal of Cell Biology (21). 
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2.4. Discussion 
 
2.4.1. Deadenylation may also occur in P bodies 
 
      Both the Pan3-Pan2 and the Ccr4-Caf1 deadenylase complexes can be enriched in P bodies of 
mammalian cells (Figs. 2.1, 2.2 & 2.6), suggesting that deadenylation may also occur in P bodies. In 
yeast, Ccr4p and Pop2p (yeast Caf1) co-localize with P bodies in strains where decapping or 5’ to 3’ 
mRNA decay is inhibited (77). It is possible that the Ccr4-Caf1 complex transits through P bodies 
quickly in yeast and therefore is only enriched in P bodies under special conditions. Moreover, at least 
some mRNAs in P bodies still have poly(A) or oligo(A) tails. Poly(A)+ transcripts can be detected in 
yeast P bodies during glucose deprivation and in stationary phase (87). In human cells, the CAT-1 
mRNA can be released from P bodies and recruited to polysomes for translation in response to different 
types of stresses (73). It is possible that some translationally inhibited poly(A)+ RNAs are targeted to P 
bodies for temporary storage, where they can either be deadenylated, decapped, and subsequently 
degraded, or released for translation before complete deadenylation.   
2.4.2. Deadenylation factors have different roles in P body formation 
 
      Our observations also indicate that Pan3, Pan2, and the Ccr4-Caf1 complex play different roles in P 
body formation. Pan3, which interacts with both PABP and Pan2, is essential for P body formation, as 
siRNA-mediated Pan3 knockdown greatly decreased P body numbers and sizes in NIH 3T3 cells (Fig. 
2.3). Co-expressed HA-Pan3 also helps ectopically expressed Pan2, Ccr4, and Caf1, but not PABP, to 
be enriched in P bodies (Fig. 2.5 & 2.6). Interestingly, the deadenylase Pan2 seems to be dispensable for 
P body formation, although it interacts with Pan3 and colocalizes with P bodies. siRNA-mediated knock 
down of the deadenylase Pan2 had little effect on P body formation (Fig. 2.4 A&B), which is consistent 
with the observation that over expression of catalytically mutant Pan2 had no effect on P bodies in NIH 
3T3 cells (Fig. 2.4 C). Our results suggest that Pan3 has functions independent of Pan2 in P body 
formation, which will be addressed in Chapter three.  
Page | 38 
 
      The deadenylase activity of the Ccr4-Caf1 complex is essential for P body formation in mammalian 
cells.  siRNA-mediated knockdown of Caf1 inhibited P body formation in NIH 3T3 cells (21)  and Ccr4 
knockdown blocked P body formation in Hela cells (74). Over expression of catalytic mutant of either 
Caf1 or Ccr4 inhibited deadenylation (Fig. 2.8 & (16)) and blocked P body formation (Fig. 2.8 and data 
not shown). Moreover, restoring deadenylation allowed P body formation (Fig. 2.9). Collectively, these 
observations indicate that P body formation in mammalian cells requires the deadenylase activity of the 
Ccr4-Caf1 complex.  
      It is noteworthy that in yeast deletion of either Ccr4p or Pop2p (yeast Caf1) only had a small effect 
on P bodies (77), even though the Ccr4p-Pop2p complex is the major deadenylase in yeast. This 
discrepancy suggests different mechanisms for P body formation in yeast and mammalian cells. Indeed, 
yeast, but not human, P body components are more likely to contain Q/N-rich aggregation-prone regions 
(78), which may help the aggregation of associated mRNPs into P bodies.    
2.4.3. Deadenylation per se, and not just dissociation of ribosomes from mRNAs, is required for 
mammalian P body formation 
 
      Since mRNAs need to be ribosome-free to form P bodies (72, 76) and the poly(A) promotes 
translation initiation, it is likely that deadenylation allows P body formation by rendering the mRNAs 
ribosome-free. To test this possibility, cells were treated with puromycin to release ribosomes from 
mRNAs while deadenylation was inhibited either by overexpression of Caf1 mutant or siRNA-mediated 
knockdown of Caf1. To our surprise, P body formation was still blocked in cells treated with puromycin 
when deadenylation was inhibited. Our observation indicates that the importance of deadenylation in P 
body formation cannot be simply explained by the inhibitory effect of deadenylation on recruitment of 
ribosomes to the mRNAs.  
      Another reason why deadenylation is required for P body formation might be that deadenylation 
helps removal of the translation activators PABP and eIF4G from the mRNAs. eIF4G can 
simultaneously interact with both the cap-binding protein eIF4E and the poly(A) tail-binding protein 
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PABP to circularize poly(A)+ mRNAs, forming a closed-loop conformation that may inhibit P body 
localization and degradation. Indeed, neither PABP nor eIF4G is enriched in P bodies. In addition, 
deadenylation may promote the interaction between mRNAs and the Lsm1-7 complex, a decapping 
activator that prefers to bind deadenylated mRNAs (88). In summary, my experiments demonstrate a 
pivotal role of deadenylation in P body formation. 
  
2.4.4. A working model linking deadenylation and P body formation   
 
      Based on previous and current observations, the following working model is proposed to link 
deadenylation and P body formation in mammalian cells (Fig. 2.11). The PABPs on mRNA poly(A) tail 
interact with Pan3 to recruit the deadenylase Pan2, initiating the first phase of deadenylation. After the 
poly(A) tail is significantly shortened by Pan2, the remaining PABPs associated with the Poly(A) tail is 
less effective in inhibiting the deadenylase activity of the Ccr4-Caf1 complex, allowing the second 
phase of deadenylation to occur. During the first phase and/or early second phase of deadenylation, 
PABP, eIF4G, and ribosomes dissociate from the mRNPs and the mRNPs can loosely attach to P bodies.  
It may be speculated that these loose mRNPs constitute the outer layer of P bodies. At this stage, the 
mRNPs can either be released from P bodies for translation or be further deadenylated by the Ccr4-Caf1 
complex, which results in recruitment of the Lsm1-7 complex. The resultant mRNPs then form the core 
of P bodies and its mRNA component can be decapped and degraded within P bodies. One possibility is 
that when the deadenylase activity of the Ccr4-Caf1 complex is inhibited, the mRNPs cannot form the 
cores of P bodies, therefore P body formation is inhibited.   
      The proposed model helps explain why the deadenylation complexes co-localize with P bodies, why 
deadenylation is required for P body formation, why PABP, eIF4G, and ribosomes are not enriched in P 
bodies, and why some mRNAs released from P bodies can still be translated.   
 Figure 2.11:  A model linking deadenyl
 
The PABP proteins on mRNA poly(A) tail interact with Pan3 to recruit the deadenylase Pan2, 
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Chapter 3: Potential Phosphorylation of 
Pan3 N-terminal Domain in Regulating 
Pan3 Localization and Functions 
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3.1. Introduction 
 
      The Pan3-Pan2 deadenylase complex is conserved from yeast to human. In yeast, Pan3p-Pan2p 
slowly shortens mRNA poly(A) tails when the major deadenylase Ccr4p-Pop2p is deleted (31). In 
mammalian cells, the Pan3-Pan2 complex carries out the first phase of deadenylation in the cytoplasm 
by shortening mRNA tails from over 200 nt to about 110 nt before the Ccr4-Caf1 deadenylase takes 
over in the second phase of deadenylation (16, 19).  
      The N-terminal domain of Pan3 interacts with the cytoplasmic PABP, while the C-terminal domain 
of Pan3 binds deadenylase Pan2 (27, 30). By simultaneously interacting with both PABP and Pan2, 
Pan3 recruits the Pan2 to its substrate, the mRNA poly(A) tail. Interestingly, yeast Pan2p substrate 
specificity is determined by Pan3p and Pab1p (homolog of PABP), as non-poly(A) sequences bound by 
Pab1p can also be degraded by purified Pan3p-Pan2p (26). Although it is clear that Pan3 recruits Pan2 
to its substrates, Pan3 may also plays other roles in regulating Pan2 activity.  
      Mammalian Pan3 and Pan2 are enriched in cytoplasmic mRNA processing bodies (P bodies) and 
Pan3 is required for P body formation in NIH 3T3 cells (21). Yeast Pan3p and Pan2p also form 
cytoplasmic foci (36), although it is unclear whether those foci co-localize with P bodies. The co-
localization of Pan3-Pan2 with P bodies is independent of PABP, because PABP is not enriched in 
mammalian P bodies even when Pan3 is over expressed (21, 71). Ectopically expressed Pan3 helps co-
transfected Pan2 to enter P bodies (21), but it’s unclear whether Pan3’s P body localization is Pan2-
dependent.    
      Interestingly, Pan3 can be phosphorylated at multiple sites. Yeast Pan3p is a substrate of the Pho85-
Pcl1 cyclin-dependent kinase (89), a functional homolog of mammalian CDK5. Yeast Pan3p can also be 
phosphorylated at T57 and S252 upon DNA damage (90). Mouse Pan3 is phosphorylated at T41 (91), 
while human Pan3 in Hela cells is phosphorylated at S208 during G1 phase of cell cycle (34). It should 
be noted that all of the reported phosphorylation sites are within the N-terminal domain of Pan3. How 
phosphorylation affects Pan3’s functions and localizations is unknown.  
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      In this study, I generated a series of Pan3 truncation mutants to study the interplay among Pan3-
Pan2 interaction, P body localization, and mRNA degradation. Mutations in Pan3 N-terminal domain 
mimicking hyperphosphorylation or hypophosphorylation were made to study the effects of Pan3 N-
terminal domain phosphorylation on Pan3 localization and function.        
3.2. Materials and Methods 
3.2.1 Plasmids.  
      Construction of pSR-HA-hPan3 was described in Chapter 2. pSR-λN-HA-hPan3 was constructed 
by ligating synthesized λN DNA flanked by NheI and MluI sticky ends with NheI and MluI-digested 
PCR product using pSR-HA-hPan3 as template and two primers that amplify HA-Pan3 sequence and 
the plasmid backbone. The forward and reverse sequences of the NheI- λN-MluI fragment are 
CTAGCATGAACGCACGAACACGAC GACGTGAGCGTCGCGCTGAGAAACAAGCTCAAT 
GGAAAGCTGCAAAC and CGCGTGTTTGCAGCTTTCCATTGAGCTTGTTTCTCAGCGCGACG 
CTCACGTCGTCGTGTTCGTGCGTTCAT, respectively. The forward and reverse primers for 
amplifying HA-Pan3 sequence and the plasmid backbone are actagt(adaptor)ACGCGT(MluI site)-
GGTTCATACCCATACGATGTTCCAG and actagt(adaptor)GCTAGC(NheI site)-ATGAGAACCCC 
GCATGGTG.  
      pSR-HA-hPan3(166-741), pSR-HA-hPan3(288-741), pSR-HA-hPan3(354-741), pSR-HA-hPan3(1-
353), and pSR-HA-hPan3(1-588) were generated by ligating XmaI and XhoI-digested PCR-amplified 
hPan3 cDNA partial fragments with the larger fragment of XmaI and XhoI-digested pSR-HA-hPan3 
plasmid. hPan3(166-741) was PCR amplified from the pSR-HA-hPan3 plasmid template using primers 
TTCCCGGGTCTGCCTTCTCTCAAGTTTTCTCTCACC and 
GCTCGAGTCACAACTGACCATTTGC, hPan3(288-741) using primers 
TTCCCGGGATGCAACCGAAAGCAAACGCAC and GCTCGAGTCACAACTGACCATTTGC, 
hPan3(354-741) using primers aattatCCCGGG-GGATATATTACATCTTGCTACAAAGCTG and 
ATCGCTACTTAGCTAGAGCTCG, hPan3(1-353) using primers 
ATGTTCCAGATTACGCTTTAATTAAGC and 
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aattatCTCGAGAAAATTACTTGATTTCTGTATCCGGTTG, and hPan3(1-588) using 
ATGTTCCAGATTACGCTTTAATTAAGC and aataatCTCGAG-
AGTCAACAAATACAAAATCAGATTCTTCAG. pSR-HA-hPan3(1-353, 589-741) was created using 
the Quickchange kit (Stratagene) and primers that allow PCR amplification of the whole pSR-HA-
hPan3 plasmid except the cDNA encoding aa 354-588 of hPan3. The sequences of the Quickchange 
primers are GGATACAGAAATCAAGTAATGACCAAAACAGGATGCGAAGTG  and 
CACTTCGCATCCTGTTTTGGTCATTACTTGATTTCTGTATCC. pSR- λN-HA-hPan3(166-741), 
pSR- λN-HA-hPan3(288-741), pSR- λN-HA-hPan3(1-353), and pSR- λN-HA-hPan3(1-588) and 
pSR- λN-HA-hPan3(1-353, 589-741) were created similarly using pSR- λN-HA-hPan3 as template.  
      pSR-λN-HA-Pan(PM11) and pSR-λN-HA-Pan(NP11) were created in three steps. The first step 
was creation of a λN-HA-hPan3(PCD) mutant with a truncation in the potentially phosphorylated 
region which results in a unique recognition site for the blunt end restriction enzyme MscI. This was 
done using the Quickchange kit (Stratagene) and primers 
GCCCTGCTACTGCTGGCCAAACTATCATATTTATCCTCC and GTTGGAGGATAAATATGA 
TAGTTTGGCCAGCAGTAGCAGGGC. The second step was PCR amplification of the potentially 
phosphorylated regions with 11 point mutations either inhibiting or mimicking phosphorylation from 
minigenes ordered from IDT. The third step was blunt end ligation of the PCR products with the pSR-λ
N-HA-hPan3(PCD) linearized with MscI.  
3.2.2. Cell culture and siRNA transfection.  
      Lifpofectamine RNAiMAX (Invitrogen) was used for consecutive reverse and forward siRNA 
transfections of NIH3T3 B2A2 cells. For siRNA reverse transfection, 540 pmol SMARTpool Pan3 
siRNA (Thermo Fisher Scientific), nonspecific siRNA (Thermo Fisher Scientific), or Stealth Pan2 
siRNA (Duplex #1, Invitrogen) diluted with 3ml Opti-MEM serum-free medium (Invitrogen) was 
mixed with 36ul of Lifpofectamine RNAiMAX (Invitrogen) in 10-cm dishes and incubated at room 
temperature for 20 minutes. 2.4 x 106 NIH3T3 B2A2 cells re-suspended in 10ml medium containing 
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130 ng/ml Tetrocycline were added to each of the 10-cm dishes containing siRNA-RNAiMAX 
complexes, mixed well, and incubated at 37°C  (5% CO2) for 24 hrs before changing fresh medium for 
forward transfection. For the siRNA forward transfection, the siRNA-RNAiMAX complexes were 
prepared in the same way as reverse transfection, added to the reverse transfected cells in 10-cm dishes, 
and incubated at 37°C  (5% CO2) for 24 hrs. The cells were then reseeded to new 10-cm dishes, 
incubated at 37°C  (5% CO2) for 24 hrs, and collected for Western blot analysis and poly(A) tail length 
distribution profile analysis.      
3.2.3. Analysis of poly(A) tail length distribution profiles.   
      Cytoplasmic RNA was extracted using RNeasy Mini kit (Qiagen) from cytoplasmic lysate of 
transfected NIH3T3 B2A2 cells, during which the RNA was subject to on-column DNase digestion with 
the RNase-free DNase set (QIAGEN). One µg of purified cytoplasmic RNA was incubated with 10 µCi 
(5000 Ci/mmole) Cordycepin-5’ Triphosphate (PerkinElmer), 600 U Yeast poly(A) polymerase (Usb) 
and 20 U Rnasin (Promega) in 1x poly(A) polymerase reaction buffer at 37 °C for 20 minutes.  The 3’ 
end labeled RNA was then purified by phenol-chloroform extraction and ethanol precipitation. The 
radioactivity of the product was assayed by liquid scintillation following TCA precipitation. A constant 
amount of radioactivity (1000,000 cpm) was mixed and incubated with 20 µg yeast total RNA, 0.02 µg 
RNase A (Roche), and 87 U RNase T1(Sigma-Aldrich) in a 20 µl reaction at 30 °C for 30 minutes to 
digest RNA body (RNase A cleaves 3' of U and C residues and Rnase T1 cleaves after G residues). The 
RNase digestion reaction was stopped by the addition of SDS and Proteinase K and incubation at 37 °C 
for 30 minutes. The poly(A) RNA was phenol-chloroform extracted and ethanol precipitated. The 
radioactivity of the product was assayed by TCA precipitation and liquid scintillation again. A constant 
amount of radioactivity (15,000 cpm) was separated on an 8% denaturing polyacrylamide gel (with 7 M 
urea). The gel was run at 300 V until the bromophenol blue dye was running out of the gel. 
Autoradiography of the dried gel was performed at -80°C with an intensifying screen for 5.5 h. 
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3.2.4. Cell culture and plasmid transfection.  
      NIH3T3 B2A2 cells were seeded to a density of 2.4 x 106/10-cm dish in 50 ng/ml tetracycline 24 hrs 
before transfection. 40µl Lipofectamine 2000 (Invitrogen) and 1 ml Opti-MEM (Invitrogen) were mixed 
and incubated at room temperature for 5 minutes. 13 µg total DNA were diluted into 1ml Opti-MEM, 
mixed with the diluted Lipofectamine 2000, and incubated at room temperature for 25 minutes. The 
mixture was then added to the cells in a 10-cm dish and incubated at 37°C in 5% CO2 for 18-20 hours. 
For co-IP experiments, the transfected cells from each 10-cm dish were split to two 10-cm dishes and 
incubated at 37°C in 8% CO2 for 24 hours before the cells were harvest. For immuno-fluorescence 
staining experiments, the transfect cells were reseeded to glass chamber slides (BD Falcon) and 
incubated at 37°C in 8% CO2 for 24 hours before the cells were fixed. For transcriptional pulse-chase 
and Northern blot analysis, the transfected NIH3T3 B2A2 cells in each 10-cm dish were split to six 6-
cm dishes and one 35-mm dish and incubated at 37°C in 8% CO2 for 20 hours before the cells were 
grown in tetracycline-free medium for 120 minutes to induce a transcriptional pulse driven by the Tet-
off promoter of the reporter plasmid in transfected cells. At various time points after the transcription 
pulse, cells from the 6-cm dishes were harvested and saved at -80C as pellets for isolating total RNA 
and subsequent Northern blot analysis. Cells from the 35-mm dish were used for Western blot analysis. 
3.2.5. Immunoprecipitation.  
      Cytoplasmic lysate was prepared by incubating harvested cells for 10 minutes on ice in 600ul of 
lysis buffer (20 mM Tris-HCl pH 7.4 buffer, 150 mM NaCl, 1% NP-40, 1 mM Na orthovanadate, 1 mM 
Na pyrophosphate, 1 mM NaF, and 1x protease inhibitor cocktail (Roche)) and spinning down nuclei 
and cell debris at 400x g for 3 minutes at 4°C. 30 µl of the supernatant was saved as input at -80°C and 
the rest of the supernatant was incubated with 30 µl of rat monoclonal anti-HA Affinity Matrix (Roche, 
clone 3F10) in the presence of 90 µg/ml RNase A for 2 hours at 4°C. The beads were washed five times 
with the lysis buffer and boiled in 30 µl of 2x SDS loading buffer for 5 minutes. The supernatant of the 
boiled mixture was saved for Western blot analysis.    
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3.2.6. Western blot analysis.  
      Either cytoplasmic or total cell lysate was used for Western, as indicated in each figure. Preparation 
of cytoplasmic lysate was described in “Immunoprecipitation”. Total cell lysate was prepared by lysing 
the cell pellets in SDS lysis buffer (60 mM Tris-HCl pH 6.8, 2% SDS, 1x protease inhibitor cocktail 
(Roche), and 1 mM DTT) and filtering the lysate with a QIAshredder column (QIAGEN). Protein lysate 
concentration was determined by Bio-Rad Dc protein assay (Bio-Rad). Except for the 
immunoprecipitation experiment, 15 µg proteins were resolved on an 8% SDS-polyacrylamide gel and 
transferred to a PVDF membrane. The PVDF blots were probed with different antibodies as described in 
each figure. The following primary antibodies were used at indicated dilution: rabbit anti-Pan2 peptide 
antibody at 1:2,000 (Bethyl), rabbit anti-Pan3 peptide antibody at 1:1,000 (Bethyl), mouse anti-tubulin 
monoclonal antibody at 1:50,000 (Sigma-Aldrich), rat anti-HA monoclonal antibody at 1:3,000 (Roche), 
mose anti-GAPDH monoclonal antibody at 1:50,000, and goat anti-Lamin B1 polyclonal antibody at 
1:200 (Santa Cruz). After washing the membrane in 1xPBST buffer, the membrane was incubated with 
HRP-conjugated donkey anti-rabbit IgG, goat anti-mouse IgG, or rabbit anti-goat IgG at 1:5,000 for 1 
hour at room temperature. After washing in 1xPBST buffer again, the membrane was incubated with 
SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific) for 5 minutes at room 
temperature, and exposed to a SYNGENE Gnome gel documentation system (SYNGENE).   
3.2.7. Northern blot analysis.  
      RNase H treatment of cytoplasmic mRNA after annealing to Oligo dT (Invitrogen) was performed 
to generate poly(A)-- RNA. 10 µg of cytoplasmic RNA with or without RNase H treatment was 
separated using 1.4% formaldehyde agarose gel electrophoresis, transferred to GeneScreen 
Hybridization Transfer membrane (PerkinElmer), UV cross-linked to the membrane, and blotted with 
32P-labeled BBB or αGAPDH DNA probe dissolved in ULTRAhyb hybridization buffer (Ambion). 
The 32P-labeled probes were prepared by labeling PCR amplified BBB and αGAPDH fragments with 
α-[32P]dCTP (>6000 Ci/mmol; PerkinElmer) using the Rediprime II Random Prim Labeling System 
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(GE Healthcare). The probes were purified using MicroSpin G-25 columns (GE Healthcare) before used 
for hybridization.    
3.2.8. Immunofluorescence microscopy.   
      This was conducted as described in Chapter 2. Briefly, transfected NIH3T3 cells were seeded to 
chamber slides (BD Falcon) and cultured at 37°C (8% CO2) overnight before the cells were fixed. For 
sodium arsenite (Sigma-Aldrich) or Leptomycin B (Sigma-Aldrich) treatment, cells were cultured in 
medium containing 0.3mM sodium arsenite for 1 hour or 20 ng/ml Leptomycin B for 4 hours before the 
cells were fixed. Ectopically expressed HA-tagged proteins were detected using rat anti-HA monoclonal 
antibody (Roche, clone 3F10) and Alexa Fluor 350 goat anti-rat IgG (Invitrogen). Endogenous P bodies 
were detected using rabbit anti-RCK/p54 (Bethyl) or human anti-GW182 (a gift from Dr. M.J. Fritzler, 
University of Calgary, Canada) and Alexa Flour 555 goat anti-rabbit IgG (Invitrogen) or Alexa Flour 
488 goat anti-human IgG (Invitrogen). Endogenous stress granules were detected using rabbit anti-
G3BP1 (a gift from Dr. R.Lloyd, Baylor College of Medicine, USA) and Alexa Flour 555 goat anti-
rabbit IgG. All the primary and secondary antibodies used for immunofluorescence staining were 
diluted at 1:1,000. 
      Images were obtained at RT by optical z-sectioning (20 sections in total, 0.2-μm-space between 
sections) using an objective lens (100×/1.35 NA; Olympus) of a deconvolution microscope system 
(DeltaVision) containing an inverted microscope (IX70; Olympus). Immersion oil (n = 1.514) was from 
Applied Precision, LLC. Images were captured using a digital camera (Coolsnap HQ; Roper Scientific). 
Stacks of 20 images were projected as a single 2D picture using softWoRx Explorer (version 3.3.6; 
Applied Precision, LLC). The RGB colors of the resulting pictures were separated using Photoshop CS 
(Adobe) (21). 
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3.3. Results 
3.3.1. siRNA-mediated knockdown of Pan3 or Pan2 in NIH 3T3 cells resulted in cytoplasmic 
mRNAs with longer poly(A) tails  
 
      Although deletion of Pan3 and/or Pan2 in yeast extended poly(A) tail length of bulk mRNAs (30), 
the effect of Pan3 or Pan2 depletion on the poly(A) tail of bulk mRNA in mammalian cells has never 
been studied. Cytoplasmic mRNA from NIH 3T3 cells transfected with Pan3 or Pan2-specific or non-
specific siRNA was labeled at 3’ ends with 32P-Cordycepin (3’ deoxyadenosine) and treated with diluted 
Rnase T1 and Rnase A to remove the non-poly(A) RNA body. The resultant poly(A) tails were resolved 
on a denaturing urea-polyacrylamide gel to reveal poly(A) size distribution profile (Fig. 3.1 B). Poly(A) 
tails of cytoplasmic mRNAs from Pan3 siRNA transfected cells were significantly longer than those 
from non-specific siRNA transfected cells. Pan2 knockdown only slightly increased bulk mRNA poly(A) 
tail length, probably because the knockdown of Pan2 was not complete (Fig. 3.1 A). This result 
confirmed that Pan3 and Pan2 are general deadenylation factors in mammalian cells. 
             
  
 Figure 3.1: Effects of Pan3 knockdown on ply(A) tails of bulk cytoplasmic mRNAs in NIH 3T3
Cells.  
 
(A) Western Blot analysis of total cell lysate showing knockdown of Pan2 or Pan3 by siRNA.  
(B) Poly(A) tail length distribution profiles analyzed by denaturing urea
electrophoresis. Following transfection with Pan3 siRNA or nonspecific si
cytoplasmic RNA was isolated from NIH 3T3 cells. The RNA samples were first labeled with 
labeled Cordycepin in the presence of yeast PAP, which are then digested with Rnase A and Rnase T1 
to remove the RNA body. The resulting poly(A)
urea-polyacrylamide gel. The bands running at ~70nt, 35nt, and 25nt can sometimes be observed in the 
sample with NS siRNA treatment.
poly(A) profiling was repeated four times.)
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3.3.2. The N-terminal domain of Pan3 is dispensable for interaction with Pan2 in NIH 3T3 cells 
 
      Pan3 consists of a less conserved N-terminal domain, a pseudo kinase domain, and a conserved C-
terminal domain (Fig. 3.2A). While the PAM2 motif in Pan3 N-terminal domain is responsible for 
Pan3-PABP interaction (92), in yeast the C-terminal domain of Pan3p is responsible for interaction with 
Pan2p (33). To map the Pan2-binding domains in human Pan3, I generated a series of HA-tagged Pan3 
truncation mutants (Fig. 3.2 A) and tested their ability to pull down endogenous Pan2 in NIH 3T3 cell 
lysate by co-IP (Fig. 3.2 B). The co-IP experiment showed that deletion of the N-terminal domain (1-
353) didn’t affect Pan3-Pan2 interaction and that deletion of the pseudo kinase domain (354-588) 
significantly decreased the Pan3-Pan2 interaction, while deletion of the C-terminal domain (589-741) 
abolished Pan3-Pan2 interaction. These results indicate that human Pan3 C-terminal domain is required 
for interaction with Pan2 and that the pseudo-kinase domain enhances Pan2-Pan3 interaction.  In 
contrast, the N-terminal domain is dispensable for Pan3-Pan2 interaction.  
 Figure 3.2: Only the C
domain of Pan3 is required for 
interaction with Pan2 in NIH 3T3 
cells.  
(A) Schematic representation of wild 
type Pan3 and Pan3 truncation mutants. 
PAM2 motif is responsible for Pan3
PABP interaction.
(B) Western blot analysis showing HA
tagged proteins and endogenous Pan2 in 
cytoplasmic inpu
and in complexes precipitated by anti
HA antibody conjugated to agarose 
beads (Lower two panels). Mock 
transfected cell lysate was used as a 
negative control to show the specificity 
of the precipitation.
experiment was repeat
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3.3.3. Domain requirement for tethered Pan3 to promote rapid deadenylation and decay of the 
reporter mRNA 
 
      Pan3 interacts with both PABP and deadenylase Pan2 to recruit Pan2 to the mRNA poly(A) tail 
associated with PABP (27, 33, 92, 93). To understand whether Pan3 simply recruits Pan2 or also 
regulates Pan2 nuclease activity, λN-tagged Pan3 or Pan3 mutants were co-expressed with the reporter 
mRNA BBB-4boxB and decay kinetics of the reporter mRNA in the cytoplasm of the NIH3T3 B2A2 
cells were studied by Tet-off driven transcriptional pulse-chase experiments (Fig. 3.3 A) (81). The λN 
tag, which is a 22 amino acid peptide derived from the N-terminus of the lambda bacteriophage N 
protein, can specifically bind the boxB sequences in the 3’ untranslated region (UTR) of the reporter 
mRNA (94).  
      As expected, tethering wild type Pan3 but not LacZ promoted deadenylation and decay of the 
reporter mRNA in the cytoplasm (Fig. 3.3 C, D). In contrast, the stability of the cytoplasmic reporter 
mRNA was not affected by tethering Pan3 mutants with deletion in N-terminal domain, pseudo kinase 
domain, or C-terminal domain (Fig. 3.3.E-G). It is not surprising that tethering Pan3(1-588) did not 
promote rapid deadenylation and decay of the reporter mRNA, since Pan3(1-588) cannot interact with 
the deadenylase Pan2 (Fig. 3.3 F). However, both Pan3(288-741) and Pan3(1-353, 589-741), which 
were able to interact with Pan2 (Fig. 3.2 B), also failed to stimulate reporter mRNA deadenylation and 
decay when tethered (Fig. 3.3 E, G), suggesting that while Pan3 C-terminal domain is responsible for 
recruiting Pan2, Pan3 N-terminal and pseudo kinase domains are also important for stimulating Pan2 
deadenylase activity.      
 
 Figure 3.3: Effects of tethered 
on the decay kinetics of the reporter mRNA BBB
 
(A) NIH3T3 B2A2 cells were transiently transfected with a 
encoding the reporter mRNA BBB
indicated. A plasmid encoding constitutively expressed alpha
co-transfected to provide an internal standard for t
(B) Western blot analysis of total cell lysate showing expression levels of 
for the tethering experiment. Endogenous GAPDH was used as a loading control. (
Northern blots showing cytoplasmi
LacZ (C), λN-HA-Pan3(D), 
Pan3(1-353, 589-741) (G). The times given at the top correspond to hours after tetracycline 
addition. Poly(A)- RNA (A-
time point with oligo(dT) and RNase H.
λN-HA-LacZ, λN-HA-Pan3, or λN-HA-Pan3 truncation mutants 
-4boxB.  
Tet promoter–regulated plasmid 
-4boxB and the plasmids encoding λN-tagged proteins as 
-globin–GAPDH mRNA was also 
ransfection efficiency and sample handling. 
λN
c decay of the BBB-4boxB mRNA tethered with 
λN-HA-Pan3(288-741) (E), λN-HA-Pan3(1-588) (
) was prepared in vitro by treating an RNA sample from an early 
 (This experiment was repeated once.)
Page | 54 
  
-tagged proteins 
C-G) 
λN-HA-
F), λN-HA-
 
Page | 55 
 
3.3.4. The N-terminal domain and pseudo kinase domain, but not the C-terminal domain, are 
important for Pan3 to form many foci in NIH 3T3 cells 
 
      Pan3 not only co-localizes with P bodies but also is required for P-body formation in mammalian 
cells (21).  However, it was unclear which domains of Pan3 are important for its P body localization and 
whether Pan3 is dependent on Pan2 for localizing to P bodies. To address these questions, the 
aforementioned Pan3 truncation mutants were transiently expressed in NIH 3T3 cells and their sub-
cellular localization were examined using indirect immuno-fluorescence microscopy (Fig. 3.4). Anti-
HA and anti-RCK/p54 antibodies were used to detect the HA-tagged Pan3 wt or mutants and 
endogenous P bodies, respectively. Consistent with what we reported before, wild type Pan3 was mainly 
cytoplasmic and forms many foci co-localizing with endogenous P bodies. Except the kinase domain 
deletion mutant (Fig. 3.4 F), all other mutants showed increased nuclear distribution and were somewhat 
able to localize to cytoplasmic P bodies. The expression level of HA-Pan3(354-741) was so low that I 
did not find cells expressing HA-Pan3(354-741) under microscope. Interestingly, the Pan3 mutant with 
most of the N-terminal domain deleted only formed a few foci (Fig. 3.4 C), while the Pan3 mutant with 
C-terminal domain deleted still formed many foci (Fig. 3.4 D), suggesting that the N-terminal domain of 
Pan3 is responsible for Pan3 colocalization with P-bodies in the cells. This experiment also indicated 
that interaction with Pan2 is not required for Pan3 to enter P bodies, since the C-terminal domain 
deletion mutant that no longer interacts with Pan2 could still co-localize with P bodies (Fig. 3.4 D, E).  
Collectively, these results showed that both N-terminal and pseudo-kinase domains, but not C-terminal 
domain, are necessary for Pan3 to colocalize with P bodies.  Intriguingly, the N-terminal domain by 
itself was sufficient to localize to P bodies. 
  
Figure 3.4: Indirect immuno
fluorescence staining showing 
sub
HA
truncation mutants and the P 
body marker RCK/p54. 
 
(A
many cytoplasmic foci 
colocalizing with P bodies.
(B
to most P bodies when half 
of 
domain 
(C
Pan3 
impaired P
form many cytoplasmic foci
 (
C
was still able to 
cytoplasmic foci
(E
alone was able to colocalize 
with P bodies.
(F
kinase domain completely 
abolished the ability of Pan3 
to 
(This experiment was repeated 
twice.)
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3.3.5. Pan3 N-terminal domain may be phosphorylated to regulate Pan3 localization and/or 
function  
 
      Since Pan3 N-terminal domain is important for Pan3 to stimulate Pan2 activity and to localize to P 
bodies, I decided to take a close look at this domain. An alignment of Pan3 sequences from different 
species revealed that the N-terminal domain is less conserved than the other domains (Fig. 3.5 A). 
However, the N-terminal domains of all the analyzed Pan3 sequences are proline-rich. Since the 
conformation of proline is rigid, proline-rich motifs often tend to form disordered regions that are 
difficult to characterize by NMR spectroscopy or X-ray diffraction (95). Indeed, the N-terminal domains 
of both human and yeast Pan3 are predicted to be intrinsically disordered by the VL-XT software(96).  
  
Figure 3.5: Human Pan3 N-terminal domain contains a conserved proline
 
(A) Alignment of Pan3 protein sequences from yeast, xenopus, mouse and human using ClustalW2. 
Proline residues are highlighted in yellow. (
Pan3 (B) and yeast Pan3 (C) using VL
considered to be disordered by the VL
 
-rich, disordered region. 
B-C) Prediction of intrinsically disordered region in human 
-XT from PONDR. Regions with a ponder score above 0.5 are 
-XT.  
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      Both proline-rich motifs and intrinsically disordered regions are often target sites for 
phosphorylation and are involved in protein-protein interaction (95, 97). HA-tagged wild-type Pan3 and 
Pan3 N-terminal domain appeared as double bands on the Western blot membrane and the upper band 
was sensitive to calf intestinal alkaline phosphotase (CIAP) treatment (Fig. 3.6 A), suggesting that Pan3 
N-terminal domain indeed can be phosphorylated in NIH 3T3 cells.  
      Two different online tools were used to predict phosphorylated residues in Pan3 N-terminal domain. 
The first tool is DEEP (Disorder Enhanced Phosphorylation Predictor), which predicts phosphorylation 
sites based on both disorder information and position-specific amino acid frequencies (98). The second 
tool, ScanSite 2.0, can identify short protein sequence motifs that are substrates for protein Ser/Thr- or 
Tyr-kinases (99). Although the two tools use different methods to predict protein phosphorylation sites, 
they both predicted that a small region around a.a. residue 200 in Pan3 N-terminal domain is likely 
hyperphosphorylated (Fig. 3.6 B, C).  
      To study the functional significance of Pan3 N-terminal domain phosphorylation, eleven predicted 
phosphorylation sites around residue 200 in λN-HA-tagged Pan3 were mutated to either inhibit or 
mimic phosphorylation at those sites. The sequences of part of the N-terminal domain of wild type Pan3, 
Pan3 mutant nonphosphorylatable at the eleven sites(NP11), and phosphor-mimetic Pan3 mutant (PM11) 
were aligned, with the mutated residues highlighted in white background (Fig. 3.6 D). Western blot 
analysis showed that both λN-HA-tagged Pan3(PM11) and λN-HA-tagged Pan3(NP11) were 
expressed in NIH 3T3 cells after transient transfection (Fig. 3.6 E).  
 Figure 3.6: Mutagenesis to mimic or inhibit phosphorylation in the disordered region of Pan3. 
 
(A) Western blot analysis of HA
domain (Right panel) in CIAP treated or mock treated cell lysate. 
was repeated once; CIAP treatment of Pan3(1
phosphorylation sites using PONDR. (
Local sequence alignment of wild
eleven residues with white background are mutated to either mimic phosphorylation (PM11) or inhibit 
phosphorylation (NP11). (E) We
HA-tagged wild type Pan3, Pan3(NP11), and Pan3(PM11). 
 
-tagged wild-type Pan3 (Left panel) or HA-tagged Pan3 N
(CIAP treatment of wild
-353) was performed only once.)(B) Prediction of Pan3 
C) Prediction of Pan3 phosphorylation sites using ScanSite. (
-type Pan3, Pan3(NP11), and Pan3(PM11) using ClustalW2. The 
stern blot analysis of total cell lysate showing the expression of 
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      Interestingly, mutations at the eleven potential phosphorylation sites in Pan3 N-terminal domain 
dramatically changed Pan3 localization. While λN-HA-tagged Pan3 mostly formed cytoplasmic foci 
co-localizing with P bodies (Fig. 3.7 A), λN-HA-tagged Pan3(NP11) mimicking hypo-phosphorylation 
in Pan3 N-terminal domain induced formation of large, irregularly shaped speckles co-localizing with P 
bodies (Fig. 3.7 B). On the other hand, λN-HA-tagged Pan3(PM11) mimicking hyper-phosphorylation 
in Pan3 N-terminal domain induced formation of nuclear foci (Fig. 3.7 C), similar to the localization of 
HA-tagged Pan3(1-353) (Fig. 3.4 E). Moreover, λN-HA-tagged Pan3(PM11) in the cytoplasm no 
longer enriches in P bodies (Fig. 3.7 C).      
  
 Figure 3.7 Mutations at the potential phosphorylation
dramatically changed Pan3 localization.
 
Immuno-fluorescence staining showing the localization of the P body marker RCK/p54 and 
tagged wild type Pan3 (A), Pan3(NP11) (
  
 
 sites in Pan3 N-terminal domain 
 
B), or Pan3(PM11) (C). (This experiment was repeat
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      The λN-HA-tagged Pan3(PM11) nuclear foci resemble the nuclear HA-tagged Pan3 foci formed 
upon leptomycin B (LMB) treatment, which inhibits CRM1-mediated nuclear export (100) (Fig. 3.8 A). 
Interestingly, LMB treatment also increased the relative intensity of the upper band of HA-Pan3 (Fig. 
3.8 B). It is possible that LMB treatment resulted in both Pan3 nuclear localization and hyper-
phosphorylation.  
  
 
Figure 3.8: Effects of Leptomycin B treatment on HA
 
(A) Immuno-fluorescence staining showing the localization of HA
treatment. (B) Western blot analysis of total cell lysate showing that Leptomycin B (LMB) treatment 
may affect phosphorylation of HA
-tagged Pan3.  
-tagged Pan3 upon Leptomycin 
-tagged Pan3. (This experiment was performed once.)
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      The observation that sub-cellular localizations of λN-HA-tagged Pan3(PM11) and Pan3(NP11) are 
distinct from that of λN-HA-tagged Pan3 suggests that these mutants may have effects different from 
Pan3 on mRNA decay kinetics. To test this possibility, Pan3(PM11) or Pan3(NP11) was tethered to the 
3’UTR of the reporter pTet-BBB-4boxB through specific λN-boxB interaction, followed by Tet-off 
driven transcriptional pulse-chase experiments for studying reporter mRNA decay kinetics. The results 
showed that tethering either one of Pan3, Pan3(PM11), or Pan3(NP11) promoted cytoplasmic 
deadenylation and decay of the reporter mRNA BBB-4boxB (Fig. 3.9). These results strongly suggest 
that phosphorylation status of the eleven residues in Pan3 N-terminal domain does not directly affect 
Pan3’s ability to promote rapid deadenylation and decay.  Instead, it affects Pan3 subcellular 
localization. 
  
 Figure 3.9: Effects of tethered Pan3(PM11) or 
 
 (A) Western blot analysis of total cell lysate showing expression of 
tethering experiment. (B-D) Northern blots showing cytoplasmic decay of the BBB
tethered with λN-HA-Pan3 (B
encoding constitutively expressed alpha
internal standard for transfection efficiency and sample handling. The times given at the top corr
to hours after tetracycline addition. Poly(A)
sample from an early time point with oligo(dT) and RNase H. 
Pan3(NP11) on reporter mRNA decay.
λN-HA-tagged proteins for the 
), λN-HA-Pan3(PM11) (C), and λN-HA-Pan3(NP11) 
-globin–GAPDH mRNA was also co-transfected to provide an 
- RNA (A-) was prepared in vitro by treating an RNA 
(This experiment was performed once.)
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3.4. Discussion 
 
      In this study, I showed that siRNA-mediated knockdown of Pan3 resulted in bulk cytoplasmic 
mRNAs with longer poly(A) tails in NIH 3T3 cells(Fig. 3.1).  Pan2 knockdown had a similar but 
weaker effect, probably because the knockdown was not complete (Fig 3.1). This phenotype is 
reminiscent of that observed in budding yeast, where Pan3p-Pan2p was reported to trim the poly(A) tails 
of newly synthesized transcripts to message-specific length [35], although it was unclear whether this 
trimming occured in the nucleus or in the cytoplasm. Interestingly, my preliminary data showed that 
HA-tagged wild-type Pan3 formed nuclear foci when the cells were treated with leptomycin B (Fig. 3.8). 
This observation is consistent with a speculation that the Pan3-Pan2 complex may trim the poly(A) tails 
of nascent transcripts at the transcription sites. 
       A novel role for Pan3 in regulating Pan2 poly(A) nuclease activity is also suggested by my domain 
dissection study on Pan3. Tethering wild-type Pan3, but not the Pan3 mutant deficient in Pan2 
interaction, promoted deadenylation and degradation of the reporter mRNAs in NIH 3T3 cells (Fig. 3.2 
& Fig. 3.3 F), suggesting that interaction with Pan2 is important for Pan3 to promote deadenylation. 
Interestingly, tethering Pan3 mutant that lacks N-terminal domain or pseudo-kinase domain but is 
capable of interacting with Pan2 also did not elicit rapid deadenylation and decay of the reporter mRNA 
(Fig. 3.2 & Fig. 3.3 E&G).  These results suggest that the N-terminal and pseudo-kinase domains are 
also required for Pan3 to promote the poly(A) nuclease activity of Pan2. Since purified human Pan2 
alone can trim oligo(A) in the absence of PABP in an in vitro reaction albeit slowly [27], it is possible 
that the N-terminal domain and the pseudo kinase domain of Pan3 are required to release PABP at the 
very 3' end of the poly(A) tail, making the poly(A) tail more accessible to Pan2. Consistent with this 
idea, the Pan3 N-terminal domain indeed contains a PAM2 motif for interaction with PABP [92].      
      Previously, we have shown that deadenylation is required for mRNAs to enter or form P bodies in 
mammalian cells and that both Pan3 and Pan2 are enriched in P bodies [21]. Therefore, the Pan3-Pan2 
complex may be recruited to P bodies via aggregation of mRNPs that contain mRNAs whose poly(A) 
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tails just have been shortened by the Pan3-Pan2 complex. However, my experiments showed that 
localization of Pan3 to P-bodies is independent from its ability to interact with Pan2 or promote 
deadenylation  (Fig 3.4).  Moreover, my observation that siRNA-mediated knockdown of Pan3, but not 
Pan2, inhibited P body formation in NIH 3T3 cells (Fig. 2.3 &2.4) suggests that Pan3 plays an active 
role in P body formation. Collectively, my data indicate that in addition to playing a regulatory role in 
deadenylation, Pan3 also contributes to P body formation by exerting some kind of Pan2-independent 
function.  
      My data also suggest that the localization and functions of Pan3 are likely regulated by 
phosphorylation of a disordered region in Pan3 N-terminal domain. The proline-rich human Pan3 N-
terminal domain is predicted to contain an intrinsically disordered region by PONDR. Interestingly, 
yeast Pan3p also contains an N-terminal disordered region (Fig. 3.5), suggesting that the disordered 
region may be functionally important. As intrinsically disordered regions are frequently phosphorylated 
to regulate protein functions, I also searched the kinase target sequences in the intrinsically disordered 
region of Pan3 N-terminal domain by Scansite (Fig. 3.6).  Phosphotase treatment greatly reduced the 
relative intensity of the upper band of HA-Pan3 and HA-Pan3 N-terminal domain doublet on Western 
blot membranes (Fig. 3.5 & 3.6), suggesting that the Pan3 N-terminal domain can be phosphrylated. 
Mutations (NP11) that inhibit phosphorylation at eleven potential phosphorylation sites in Pan3 N-
terminal domain induced formation of abnormally large P bodies (Fig. 3.7). The increase of P body size 
is unlikely caused by inhibition of mRNA decay within the aberrant P bodies, as tethered Pan3(NP11) 
can still interact with Pan2 and promote decay of the reporter mRNA (Fig. 3.9). Therefore, it is possible 
that phosphorylation of some of these residues may be required for Pan3 in P bodies to be released back 
to the cytosol. On the other hand, Pan3(PM11), which contains mutations that mimic phosphorylation at 
the eleven potential phosphorylation sites, is diffused in the cytoplasm, but highly enriched in nuclear 
foci (Fig. 3.7). Although the distinct localization phenotypes of Pan3(NP11) and Pan3(PM11) might 
stem from structural defects caused by the mutations, it is also possible that phosphorylation states of 
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Pan3 N-terminal domain may determine the localization and function of Pan3. It will be important to 
confirm that endogenous Pan3 N-terminal domain indeed is hyper-phosphorylated. 
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4.1. Introduction 
 
      mRNA processing bodies (P bodies) are dynamic cytoplasmic foci containing non-translating 
messenger ribonucleoproteins (mRNPs) as well as proteins for translational inhibition and mRNA 
degradation. Conserved from yeast to human, P bodies have a diameter of 100-300 nm (65). These 
membrane-free structures are mainly anchored to microtubules while constantly moving around in the 
cytoplasm (66). Fluorescence microscopy studies revealed that P bodies contain translationally inhibited 
mRNAs and many proteins involved in translational inhibition and mRNA degradation (68). In contrast, 
most factors involved in mRNA translation, for example eIF4G and ribosome subunits, are normally 
absent from P bodies (71).  
      P bodies provide another potential layer of post-transcriptional gene regulation because mRNAs in P 
bodies can be translationally inhibited and either degraded or released for translation. Since P bodies are 
ribosome-free, mRNAs in P bodies cannot be translated. mRNAs in P bodies can be degraded, as 
inhibition of 5’ to 3’ decay by knocking down Xrn1 increased P body sizes and mRNA decay 
intermediates were found in P bodies (72). However, P bodies may also be temporary storage sites for 
some mRNAs before they are degraded, as suggested by an observation that a P body mRNA encoding 
cationic amino acid transporter 1 (CAT-1) was released from P bodies and subsequently translated when 
the cells were subjected to different stresses (73). Therefore, P bodies may function as a “recycle bin” 
where the fates of arrested non-translating mRNAs (either degradation or release) will be determined. 
      Although over 250 papers on P bodies or P body components in different species have been 
published, the biological role and physiological significance of P-bodies remain unclear.  Currently, a 
comprehensive list of reported P body components is not available, and our ability to study P body 
components as a whole is limited. For example, how many P body proteins have been found? How can 
they be classified based on their known functions? How do they interact with each other and other 
cellular proteins? Answers to these questions are likely to provide key insight into the biological 
functions of P bodies and thus regulation of P body dynamics. 
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     In this study, a list of P body proteins in different species reported to date is provided. Reported and 
predicted human P body proteins are then grouped based on their functions. Protein-protein interaction 
analysis reveals that many P body proteins form complex interaction networks with each other as well 
as other cellular proteins that have not been reported as P body components yet. Interestingly, some of 
these cellular proteins can interact with three or even more P body components, suggesting that these 
proteins may also localize to P bodies or be important for P body dynamics and functions.  
 
4.2. Methods and Results 
 
4.2.1. Currently reported P body protein components in different species 
 
      In order to have a comprehensive view of known P body proteins, over 250 Pubmed articles 
published since 2002 that contain various synonyms of P bodies in their titles or abstracts were 
identified. After careful examination of immunofluorescence microscopic evidence for P-body 
localization in each article, a list of currently reported P body protein components in different species 
was generated (Table. 4.1). Together, 57 human proteins, 10 mouse proteins, 30 yeast proteins, and 17 
proteins from plants, worms, or fruit fly were included in the list.  
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Species Gene_ID Uniprot_Ac Name Alias Reference 
Arabidopsis 837357 Q9SJF3 DCP1  (101) 
Arabidopsis 831201 Q8GW31 DCP2  (101) 
Arabidopsis 820530 Q9LTT8 VCS  EDC4, GE-1 (101) 
C. elegans 181719 Q17740 AIN-1 GW182  (102) 
C. elegans 181504 Q20578 ALG-1  (102) 
C. elegans 175680 Q21992 LARP-1  (103) 
C. elegans 175654 Q19818 NHL-2  (104) 
C. elegans 174808 Q20374 PATR-1 Pat1 (105) 
Drosophila 36544 Q32KD4 AGO1  (106) 
Drosophila 33934 Q9VMA3 Cup  (107) 
Drosophila 39957 Q9VVI2 EDC3  (108) 
Drosophila 37528 Q9NFU0 FMRP  (109) 
Drosophila 43808 Q8SY33 GW182 Gawky (106) 
Drosophila 34364 P23128 Me31B 
Dhh1, 
RCK/P54 (110) 
Drosophila 32926 Q9V3F9 Out  (107) 
Drosophila 37065 P25159 Staufen  (109) 
Drosophila 39430 Q9VTZ0 Tral 
RAP55, 
LSM14A (108) 
Human 26523 Q9UL18 Ago1 EIF2C1 (111) 
Human 27161 Q9UKV8 Ago2 EIF2C2 (111) 
Human 192669 Q9H9G7 Ago3 EIF2C3 (112) 
Human 192670 Q9HCK5 Ago4 EIF2C4 (113) 
Human 200316 Q8IUX4 APOBEC3F  (114) 
Human 60489 Q9HC16 APOBEC3G  (114) 
Human 29883 Q9UIV1 Caf1 CNOT7 (21) 
Human 57472 Q9ULM6 Ccr4 CNOT6 (76) 
Human 64506 Q9BZB8 CPEB1  (115) 
Human 55802 Q9NPI6 Dcp1a  (71) 
Human 196513 Q8IZD4 Dcp1b  (76) 
Human 167227 Q8IU60 Dcp2  (116) 
Human 80153 Q96F86 Edc3  LSM16 (117) 
Human 1977 P06730 eIF4E  (74) 
Human 56478 Q9NRA8 eIF4E-T EIF4ENIF1 (74) 
Human 10922 Q14296 FAST FASTK (71) 
Human 23644 Q6P2E9 Ge-1 
EDC4, 
HEDLS (118) 
Human 25929 Q8TEQ6 Gemin5  (119) 
Human 220988 P51991 hnRNP A3  (120) 
Human 3064 P42858 Htt  (121) 
Human 10526 O15397 Imp8 IPO8 (122) 
Human 79727 Q9H9Z2 Lin28  ZCCHC1 (123) 
Human 27257 O15116 LSm1  (124) 
Human 57819 Q9Y333 LSm2  (124) 
Human 27258 P62310 LSm3  (124) 
Human 25804 Q9Y4Z0 LSm4  (124) 
Human 23658 Q9Y4Y9 LSm5  (124) 
Human 11157 P62312 LSm6  (124) 
Human 51690 Q9UK45 LSm7  (124) 
Human 92312 A1L020 Mex-3A  (125) 
Human 84206 Q6ZN04 Mex-3B  (125) 
Human 4343 Q9HCE1 MOV10  (126) 
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Human 340152 A2A288 P58(TFL)  (127) 
Human 9924 Q504Q3 Pan2 USP52 (21) 
Human 255967 Q58A45 Pan3  (21) 
Human 219988 Q86TB9 PatL1  (128) 
Human 5093 Q15365 PCBP1 HNRPE1 (129) 
Human 5094 Q15366 PCBP2 HNRPE2 (130) 
Human 5610 P19525 PKR  (131) 
Human 55629 Q9NPJ4 PNRC2  (132) 
Human 26065 Q8ND56 RAP55 LSM14A (133) 
Human 1656 P26196 RCK/p54 DDX6  (75) 
Human 6737 P19474 Ro52 SSA1 (134) 
Human 23381 Q9UPR3 SMG5  (135) 
Human 23293 Q86US8 SMG6  (70) 
Human 9887 Q92540 SMG7  (135) 
Human 27327 Q8NDV7 TNRC6A GW182 (136) 
Human 23112 Q9UPQ9 TNRC6B  (136) 
Human 57690 Q9HCJ0 TNRC6C  (137) 
Human 10766 Q14106 Tob2  (49) 
Human 3842 Q92973 TNPO1 TRN (138) 
Human 7538 P26651 TTP Tis11, Zfp36 (138) 
Human 5976 Q92900 UPF1  (135) 
Human 65110 Q9H1J1 UPF3a  (70) 
Human 65109 Q9BZI7 UPF3b  (70) 
Human 54464 Q8IZH2 Xrn1  (124) 
Human 4904 P67809 YB-1 YBX1 (139) 
Mouse 15572 Q61701 HuD Elavl4 (140) 
Mouse 232943 Q91W40 KLC3  (141) 
Mouse 83557 Q8K3Y3 Lin28   (123) 
Mouse 636931 Q1PSW8 mLin41   (142) 
Mouse 
Mouse 
378430 
244551 
P60322 
P60324 
Nanos2 
Nanos3  
(143) 
(144) 
Mouse 170722 Q80SZ6 NXF7  (120) 
Mouse 22695 P22893 TTP Tis11, Zfp36 (71) 
Mouse 
Mouse 
Yeast 
317755 
545824 
854016 
Q80SU3 
C3VD30 
Q12517 
Zar1 
Zar1L 
Dcp1p  
(67) 
(67) 
(72) 
Yeast 855605 P53550 Dcp2p  (72) 
Yeast 854344 Q12123 Dcs2  (145) 
Yeast 854379 P06634 Ded1p   (146) 
Yeast 851394 P39517 Dhh1p  (72) 
Yeast 851787 Q03466 Ebs1p  (147) 
Yeast 856700 P39998 Edc3p LSM16 (148) 
Yeast 853318 P47017 Lsm1p  (72) 
Yeast 854504 P19524 Myo2p  (149) 
Yeast 850455 P25655 Not1p  (150) 
Yeast 851389 P06100 Not2p  (150) 
Yeast 854773 P06102 Not3p  (150) 
Yeast 856799 P34909 Not4p  (150) 
Yeast 850440 P25644 Pat1p  (72) 
Yeast 852391 P38254 Pby1p  (151) 
Yeast 
Yeast 
855788 
850647 
P39008 
Q07807 
Pop2p 
Puf3p  
(77) 
(152) 
Yeast 852513 P32831 Rbp1p Ngr1p (153) 
Page | 75 
 
Yeast 853301 P20433 Rpb4p  (154) 
Yeast 852013 P34087 Rpb7p  (155) 
Yeast 854883 Q02773 Rpm2p  (156) 
Yeast 856351 P10080 Sbp1p  (157) 
Yeast 855898 P06245 Tpk2  (158) 
Yeast 853688 P05986 Tpk3  (158) 
Yeast 854889 P09733 Tub1  (151) 
Yeast 855104 P30771 Upf1p  (69) 
Yeast 856476 P38798 Upf2p  (69) 
Yeast 852963 P48412 Upf3p  (69) 
Yeast 854541 Q08831 Vts1p  (159) 
Yeast 852702 P22147 Xrn1p Kem1p (72) 
 
 Table 4.1 A comprehensive list of reported P body components in different species. The list was 
manually generated based on published research articles in Pubmed. NCBI Gene IDs and Uniprot 
Accession Numbers are provided for the convenience of future bioinformatic analysis. 
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4.2.2. Functional categorization of reported and predicted human P body components 
 
      Most of the P body components are conserved across species, but the localization of some of the P 
body proteins was only studied in non-human species. Since the functions and localizations of many P 
body components are conserved across eukaryotes, we assume that human orthologs of P body proteins 
found in other species will also localize to human P bodies. The NCBI HomoloGene database was 
searched and 22 potential human P body components whose orthologs have been reported to localize to 
P bodies in other species were identified (Table 4.2, italic rows). To better understand the functions of 
human P body components, the reported and predicted human P body proteins were clustered based on 
their known functions (Table 4.2).  
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Gene Name Alias Homolog in 
PBs 
Function(s) Reference 
ARE-mediated mRNA degradation   
TRN 
 
 
 
TNPO1 
 
 
 
 Nuclear transport receptor; trafficking of TTP 
between the PBs and SGs and modulates ARE-
containing mRNA stability. 
(138, 160) 
TTP ZFP36  Binds to and destabilize some mRNAs with AU-
rich elements   
(161, 162) 
Nonsense-mediated decay   
PNRC2   A bridge between the mRNA decapping complex 
and the NMD machinery 
(132) 
SMG5 EST1B  Required for the dephosphorylation of UPF1  (135, 163) 
SMG6 EST1A  Required for the dephosphorylation of UPF1. 
Telomere maintenance  
(70, 164, 165) 
SMG7 EST1C  Binds to phosphorylated UPF1; Triggers mRNA 
decay  
(135, 166) 
UPF1   Binds to eRF1 and eRF3; Required for nonsense-
mediated mRNA decay  
(135, 167) 
UPF2  Yeast Upf2p  Bridges Upf1 to the exon junction complex  during 
nonsense-mediated mRNA decay; Stimulate 
helicase activity of Upf1  
(69, 168) 
UPF3A   Less effective than Upf3b to induce nonsense-
mediated mRNA decay  
(70, 169) 
UPF3B   Bridges Upf1 to the exon junction complex  during 
nonsense-mediated mRNA decay; Stimulate 
helicase activity of Upf1; Required for the 
phosphorylation of UPF1   
(70, 167, 168) 
Gene silencing by miRNA or siRNA   
EIF2C1 AGO1  mi/siRNA  mediated mRNA decay and 
translational repression 
(170) 
EIF2C2 AGO2  mi/siRNA  mediated mRNA decay and 
translational repression 
(170, 171) 
EIF2C3 AGO3  mi/siRNA  mediated mRNA decay and 
translational repression 
(112, 170) 
EIF2C4 AGO4  mi/siRNA  mediated mRNA decay and 
translational repression 
(113, 170) 
HTT   Contributes to RNA-mediated gene silencing 
through association with Argonaute and P bodies 
(121) 
IPO8 Imp8  Nuclear import; Function in cytoplasmic miRNA-
guided gene silencing and affects nuclear 
localization of Ago proteins 
(122, 172) 
MOV10   Interacts with Ago1 and Ago2; Required for 
siRNA-mediated mRNA cleavage 
(126) 
TNRC6A GW182  Recruited by Agonaute proteins, important for 
miRNA-mediated deadenylation and translational 
repression 
(173, 174) 
TNRC6B   Recruited by Agonaute proteins, important for 
miRNA-mediated deadenylation and translational 
repression 
(113, 136) 
TNRC6C   Recruited by Agonaute proteins, important for 
miRNA-mediated deadenylation and translational 
repression 
(19, 113) 
UPF1   Interacts with Ago1 and Ago2; Participates in 
RNA silencing 
(175) 
Negative regulation of miRNA pathway   
LIN28   Inhibits let-7 miRNA maturation; An RNA binding 
protein in PBs and SGs. 
(123, 176, 177) 
LIN41 TRIM71 Mouse Lin41 A stem cell specific E3 ubiquitin ligase for the 
miRNA pathway protein Ago2.  
(142) 
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Binding to telomere or telomerase   
hnRNPA3   Binding to the telomeric sequence; Cytoplasmic 
trafficking of RNA.  
 (120, 178, 179) 
MOV10   Inhibits production of infectious retroviruses when 
over expressed; Binds to telomere. 
(180, 181) 
PCBP2 HNRPE2  Interacts with telomeric DNA and telomerase 
RNA; mRNA stabilization and destabilization 
(182-184) 
SMG6 EST1A  Required for the dephosphorylation of UPF1. 
Telomere maintenance  
(70, 164, 165)  
Transcription    
CNOT1-4  Yeast Not1-4p Form complexes with the deadenylases CNOT6 
and CNOT7orCNOT8; Involved in mRNA splicing, 
transport, and deadenylation.   
(37, 185) 
PCBP1 HNRPE1  Transcription activation; Splicing; mRNA 
stabilization; cap-dependent mRNA translational 
inhibition; IRES-driven translation activation 
(171, 186, 187) 
POLR2G RPB7 Yeast Rpb4p The seventh largest subunit of RNA polymerase II (154) 
YB-1 YBX1  Transcription activation; Splicing enhancement; 
Translation activation by binding to 5’-UTR 
(188-190) 
Splicing   
PCBP1 HNRPE1  Transcription activation; Splicing; mRNA 
stabilization; cap-dependent mRNA translational 
inhibition; IRES-driven translation activation 
(171, 186, 187) 
YB-1 YBX1  Transcription activation; Splicing enhancement; 
Translation activation by binding to 5’-UTR 
(188-190) 
mRNA trafficking    
FMR1 FMRP Drosophila 
FMR1 
Involved in translation regulation and trafficking 
of certain mRNA. 
(109, 191, 192) 
hnRNPA3   Binding to the telomeric sequence; Cytoplasmic 
trafficking of RNA.  
 (120, 178, 179) 
KLC3  Mouse KLC3 May bind cargo and regulate kinesin activity. (141) 
MYO5C  Yeast Myo2p Granule trafficking (149, 193) 
NXF2  Mouse NXF7 Nuclear RNA export; Cytoplasmic mRNA 
localization 
(120, 194) 
STAU1  Drosophila 
Staufen 
mRNA localization and translation regulation; 
Competes  with Upf2 to interact with Upf1 to 
promote mRNA decay. 
(109, 195, 196) 
TUBA1C  Yeast Tub1p Tubulin alpha-1C chain (151) 
mRNA stabilization   
EIF4E   Binds mRNA 5' cap to stabilize mRNA and 
promote translation initiation 
(197) 
HUD ELAVL4  Mouse HuD Binds to and stabilize some AU-rich element (ARE) 
containing  mRNAs 
(198-200) 
PCBP1 HNRPE1  Transcription activation; Splicing; mRNA 
stabilization; cap-dependent mRNA translational 
inhibition; IRES-driven translation activation 
(171, 186, 187) 
PCBP2 HNRPE2  Interacts with telomeric DNA and telomerase 
RNA; mRNA stabilization and destabilization 
(182-184) 
Translation inhibition or activation   
CPEB1   During the early development, it behaves first as 
an inhibitor and later as an activator of translation. 
(115) 
DDX6 RCK/p54 Required for microRNA-induced gene silencing (75) 
EIF2C2 AGO2  Competes with eIF4E to bind to the 5' cap to 
inhibit translation 
(201) 
EIF4E   Binds mRNA 5' cap to stabilize mRNA and 
promote translation initiation 
(197) 
EIF4ENIF1 EIF4T  Mediates the nuclear import of EIF4E. Interacts 
with the cap binding protein 4E to inhibit 
translaiton. 
(74, 202) 
GEMIN5   Inhibits both cap-dependent and IRES-driven 
translation initiations 
(203) 
PatL1   May be a decapping activator and translation (128) 
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repressor 
PCBP1 HNRPE1  Transcription activation; Splicing; mRNA 
stabilization; cap-dependent mRNA translational 
inhibition; IRES-driven translation activation 
(171, 186, 187) 
RAP55 TRAL  Translation inhibition (204) 
YB-1 YBX1  Transcription activation; Splicing enhancement; 
Translation activation by binding to 5’-UTR 
(188) 
Deadenylation   
CNOT1-4  Yeast Not1-4p Form complexes with the deadenylases CNOT6 
and CNOT7orCNOT8; Involved in mRNA splicing, 
transport, and deadenylation.   
(37) 
CNOT6 Ccr4  Deadenylase required for second phase of 
deadenylation 
(19, 21, 76) 
CNOT7 Caf1  Deadenylase required for second phase of 
deadenylation 
(21) 
NANOS2  Mouse Nanos2 Recruits Ccr4-NOT deadenylation complex to 
mRNAs 
(143) 
PAN3   Interacts with both PABP and the deadenylase 
Pan2 to stimulate Pan2 activity 
(27, 92) 
PAN2   Deadenylase required for first phase of 
deadenylation 
(16, 21) 
TOB2   Interacts with PABP and recruit the deadenylase 
Caf1 
(49) 
Decapping      
DCP1A 
  
Decapping enzyme subunit (71) 
DCP1B   Decapping enzyme subunit (76) 
DCP2   Catalytic subunit of decapping enzyme (76, 116) 
EDC3    Interact with multiple components of the 
decapping machinery, including DCP1, DCP2, and 
DDX6 
(205-207) 
GE-1 Hedls, EDC4 Promotes complex formation between DCP1A and 
DCP2. Enhances the catalytic activity of DCP2 
(118, 205) 
LSM1-7   Sm-like protein complex, decapping activator  (88, 124) 
PATL1   May function as a decapping activator and 
translation repressor 
(128) 
5' to 3' Exonuclease activity   
XRN1   5' to 3' riboexonuclease (124, 208) 
Helicase activity    
DDX3Y  Yeast Ded1p  Probable ATP-dependent RNA helicase. (146) 
DDX6 RCK/p54  Helicase activity is required for translational 
inhibition and P body formation. 
(209) 
MOV10 
  
Probable RNA helicase; interacts with Ago1 and 
Ago2; Required for siRNA-mediated mRNA 
cleavage 
(126) 
UPF1   Helicase activity is required to promote mRNA 
decay. 
(210, 211) 
Endonuclease activity   
EIF2C2 Ago2  Cleaves both passenger strand and mRNA targets 
of siRNAs 
(212, 213) 
SMG6   Functions in nonsense-mediated decay (214, 215) 
ZC3H12D  P58(TFL) Probable endonuclease  
Protein kinase activity   
EIF2AK2 PKR  Phosphorylates eIF2alpha to inhibit translation in 
virus infected cells; Targeted to PBs by the E6 
oncoprotein of HPV 
(131, 216) 
FAST FASTK  In response to Fas receptor ligation, it 
phosphorylates TIA1, an apoptosis-promoting 
nuclear RNA-binding protein.  
(217) 
PRKACB  Yeast Tpk2p Mediates cAMP-dependent signaling triggered by 
receptor binding to GPCRs. 
(218) 
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PRKX  Yeast Tpk3p A serine threonine protein kinase that has 
similarity to the catalytic subunit of cyclic AMP 
dependent protein kinases.  
(219) 
Ubiquitin ligase activity    
LIN41 TRIM71 Mouse Lin41 A stem cell specific E3 ubiquitin ligase for the 
miRNA pathway protein Ago2  
(142) 
TRIM21 Ro52  E3 ubiquitin ligase; interacts with Dcp2 to enhance 
its decapping activity 
(134, 220) 
Cap-binding activity    
EIF2C2 AGO2  Compete with eIF4E to bind to the 5' cap to inhibit 
mRNA translation. 
(201) 
EIF4E   Binds mRNA 5' cap to stabilize mRNA and 
promote translation initiation 
(197) 
GEMIN5   Binds to m7G cap of mRNAs (221) 
Response to virus    
APOBEC3F   A cytidine deaminase that restricts retroviral 
replication 
(222) 
APOBEC3G  A cytidine deaminase that restricts retroviral 
replication 
(222) 
EIF2AK2 PKR  Double-stranded RNA protein kinase targeted to 
PBs by the E6 oncoprotein of HPV 
(131, 216) 
MOV10   Inhibits production of infectious retroviruses when 
over expressed; Binds to telomere. 
(126, 180, 181) 
Miscellaneous    
LARP1  C. elegans 
LARP-1 
RNA binding (223) 
MEX-3A   RNA binding protein; May be involved in post-
transcriptional regulatory mechanisms. 
(125) 
MEX-3B   RNA binding protein; May be involved in post-
transcriptional regulatory mechanisms. 
(125, 224) 
NANOS3  Mouse Nanos3 Germ cell-specific RNA binding protein (225) 
ZAR1  Mouse ZAR1 Zygote arrest protein 1 (67) 
ZAR1L  Mouse ZAR1L ZAR1-like protein (67) 
 
Table 4.2: Functional categorization of reported and predicted human P body components.                  
P body proteins predicted based on homology are in italic. Some P body proteins with diverse functions 
are listed in different groups.  
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4.2.3. Protein-protein interactions among P body components 
 
      Proteins often exert their functions through interactions with other protein molecules.  To understand 
how different P body components aggregate to form microscopically visible foci and how P body 
components are functionally linked, protein-protein interactions (PPIs) among P body components 
themselves were analyzed. To this end, 79 gene names of reported and predicted human P body 
components were submitted to the STRING database version 8.2 to retrieve 90 PPIs among human P 
body proteins detected by anti-tag coimmunoprecipitation (coIP), yeast two-hybrid, and pulldown 
experiments. (226). Another 32 PPIs were identified by manually checking recent publications about P 
body components. The 122 PPIs among 55 of the 79 reported and predicted P body components were 
then visualized using Cytoscape version 2.6.3 (227). Proteins with similar or related functions are 
represented with similarly colored nodes, and interactions among the proteins were denoted by lines 
(Fig. 4.1). It should be noted that the interactions detected by coIP experiments are not necessarily direct.  
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Figure 4.1: Protein-protein interactions among P body components. 120 PPIs among 55 of the 79 
reported and predicted P body components were visualized using Cytoscape version 2.6.3. Cyan nodes: 
nonsense-mediated decay factors; blue nodes: miRNA-mediated gene silencing factors; pink nodes: 
ARE-mediated decay factors; red nodes: decapping factors; yellow nodes: deadenylation factors. Lines 
between the nodes represent protein-protein interactions retrieved from STRING or recent publications 
in Pubmed.    
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4.2.4. Protein-protein interactions between P body proteins and other cellular proteins 
 
      Currently little is known about how P body assembly and disassembly is elicited and regulated and 
what may be the participating protein factors.  Since proteins often alter their functions and subcellular 
localization through interactions with other proteins, we reasoned that proteins involved in controlling P 
body dynamics and/or themselves also localizing to P bodies may do so via their interactions with P 
body component(s). PPIs between human P body proteins and other cellular proteins detected by 
affinity purification and yeast two hybrid experiments were retrieved from PINA which integrates PPI 
data from six databases (228). Retrieved PPIs were processed with a PHP script and Excel to remove 
duplicated records, records with obsolete Uniprot accession numbers, and other unnecessary 
information. The processed file was imported to Cytoscape version 2.6.3, where interactants of P body 
proteins were grouped and colored differently based on the numbers of interactions between them and P 
body factors (Fig. 4.2). P body components were represented with pink nodes in the big circle close to 
the bottom, while the nodes in the other differently colored circles represent cellular proteins that 
interact with either one (sky blue ; 410 interactions), two (blue; 85 interactions), three (purple; 32 
interactions), four (magenta; 10 interactions), five (red; 5 interactions), six (brown; 2 interactions), 
seven (yellow; 1 interaction), or eight (green; 2 interactions) P body components (Fig 4.2).       
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Figure 4.2: Interactions between P body components and other cellular proteins visualized with 
Cytoscape version 2.6.3. P body components were represented with pink nodes in the big circle close 
to the bottom, while the nodes in the other differently colored circles represent cellular proteins that 
interact with either one, two, three, four, five, six, seven, or eight P body components. Lines between 
the nodes represent protein-protein interactions based on either affinity purification and/or yeast two-
hybrid experiments.  
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      I reasoned that proteins that can interact with more P body components are more likely to affect P 
body dynamics and functions or localize to P bodies. Therefore, I listed the proteins that can interact 
with three or more P body components in Table 4.3. Their Uniprot Accession number, number of P 
body interactants, and their corresponding P body interactants were also included.   
Protein  UniprotAC 
# of 
Interactants Interactants 
PABPC1 P11940 8 CNOT7,EIF2C1,EIF2C2,EIF2C4,PAN2,PAN3,PCBP1,PCBP2,UPF1 
USP4 Q13107 8 DCP1A,DCP1B,EDC3,LSM2,LSM4,LSM6,LSM7,TRIM21 
LSM8 O95777 7 DCP1A,LSM2,LSM3,LSM4,LSM6,LSM7,UPF1 
EXOSC6 Q5RKV6 6 DCP1B,LSM1,LSM7,UPF2,XRN1,ZFP36 
SART3 Q15020 6 EIF2C1,EIF2C2,LSM2,LSM4,LSM6,LSM7 
CNOT8 Q9UFF9 5 CNOT1,CNOT2,CNOT3,CNOT6,CNOT7 
EXOSC10 Q01780 5 LSM2,UPF1,UPF2,UPF3A,XRN1 
EXOSC8 Q96B26 5 LSM1,LSM7,UPF2,XRN1,ZFP36 
SMN1 Q16637 5 GEMIN5,LSM2,LSM4,LSM6,LSM7 
SNRPE P62304 5 GEMIN5,LSM2,LSM3,LSM4,LSM5 
CNOT6L Q96LI5 4 CNOT1,CNOT2,CNOT3,NANOS2 
CNOT10 Q9H9A5 4 CNOT1,CNOT2,CNOT6,CNOT7 
DICER1 A7E2D3 4 EIF2C1,EIF2C2,EIF2C3,EIF2C4 
EEF1A1 P68104 4 EIF2C2, EIF2C3, EIF2C4, LSM3 
HNRNPA1 P09651 4 EIF2C1, EIF2C2, EIF4E, XRN1 
HSP90AA1 P07900 4 EIF2C3, EIF2C4, LSM1, EIF2AK2 
PRPF4 O43172 4 LSM2, LSM4, LSM6, LSM7 
RQCD1 Q92600 4 CNOT1, CNOT2, CNOT6,CNOT7 
SNRPD2 P62316 4 LSM2, LSM6, EIF2C4, GEMIN5 
TOB1 P50616 4 CNOT1,CNOT2,CNOT3,CNOT7 
YWHAG P61981 4 LARP1,TRIM21,EDC3,KLC3 
ARRB1 P49407 3 HNRNPA3,TUBA1C,YBX1 
ATG12 O94817 3 DDX6,HNRNPA3,MOV10 
BCL6 P41182 3 DDX6,EIF4ENIF1,LSM1 
DDX20 Q9UHI6 3 EIF2C2,GEMIN5,LSM2 
DNAJA1 P31689 3 EIF2C3,EIF2C4,LSM2 
DOM3Z O77932 3 DCP2,UPF1,XRN1 
EIF4B P23588 3 EIF2C2,EIF2C3,EIF2C4 
EXOSC2 Q13868 3 UPF1,UPF2,UPF3A 
EXOSC4 Q9NPD3 3 UPF1,UPF2,UPF3A 
FLNA P21333 3 EIF2C3,PCBP2,PRKACB 
HNRNPK P61978 3 PCBP1,PCBP2,YBX1 
HSP90AB1 P08238 3 EIF2C2,EIF2C3,EIF2C4 
ILF3 Q12906 3 EIF2C1,EIF2C2,EIF2AK2 
INTS6 Q9UL03 3 EIF4E,UPF1,UPF2 
KPNB1 Q14974 3 EIF4E,EIF4ENIF1,IPO8 
MATR3 P43243 3 EIF2C1,EIF2C2,PCBP1 
p53 P04637 3 EIF2AK2,HTT,YBX1 
PARN O95453 3 UPF1,UPF2,UPF3A 
PRMT5 O14744 3 EIF2C2,EIF2C3,EIF2C4 
PUF60 Q9UHX1 3 HNRNPA3,MOV10,PCBP1 
RBM10 P98175 3 EIF2C2,EIF2C3,EIF2C4 
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SF3A2 Q15428 3 HNRNPA3,PCBP1,YBX1 
SLC25A3 Q00325 3 EIF2C2,EIF2C3,EIF2C4 
SMG1 Q96Q15 3 UPF1,UPF2,UPF3A 
SNRPD3 P62318 3 LSM3,LSM7,GEMIN5 
USP15 Q9Y4E8 3 LSM2,LSM4,LSM6 
WDR77 Q9BQA1 3 EIF2C2,EIF2C3,EIF2C4 
YWHAB P31946 3 EDC3,LARP1,ZFP36 
YWHAH Q04917 3 KLC3,LARP1,ZFP36 
YWHAQ P27348 3 DDX6,EDC3,LARP1 
YWHAZ P63104 3 EDC3,LARP1,TRIM21 
 
   
Table 4.3: A list of cellular proteins that are reported to interact with three or more P body 
components. Proteins in bold have already been reported to be important for P body functions or 
formation. 
 
      Some of the proteins listed in Table 4.3 (e.g. CNOT6L, CNOT8, and TOB1) are paralogs of 
reported P body proteins; therefore it is not surprising that they are identified. Some are more likely to 
be involved in functions not directly related to P bodies, such as the 3’ to 5’ riboexonuclease subunits 
(EXOSC2, 4, 6, 8, and 10) and the Sm-like protein Lsm8 involved in splicing (124). Interestingly, a few 
of the proteins in Table 4.3 have already been reported to be important for P body formation or 
functions (see discussion below), such as Hsp90 and 14-3-3 families of proteins (in bold) (206, 224, 229, 
230). Therefore, these reports lend support to the feasibility of using this in silico approach to 
unraveling potential functions of P bodies and the regulation of P body dynamics.  It is very likely that 
the rest of the proteins in Table 4.3 are functionally related to P bodies.  
 
4.3. Discussion 
 
      A comprehensive list of reported P body proteins in different species has been generated during this 
study (Table 4.1).  Together, 114 proteins in different species have been reported to localize to P bodies. 
Among these P body proteins, 57 are from human, 10 from mouse, 30 from yeast, and 17 from 
Arabidopsis, C. elegans, or Drosophila. It should be noted that some of these proteins (e.g. C. elegans 
AIN-1, Drosophila GAWKY, Human TNRC6A, TNRC6B, and TNRC6C) are orthologs or paralogs.  
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      Since orthologs often have similar functions, 22 human proteins whose orthologs have been reported 
to localize to P bodies in other species are also predicted to be human P body components (Table 4.2). 
The 79 reported and predicted human P body protein components are clustered based on their functions 
(Table 4.2). This analysis has yielded some interesting conclusions and/or implications. First, P bodies 
contain proteins involved in many aspects of mRNA metabolism, including transcription, splicing, 
mRNA transport, mRNA stabilization, mRNA translational inhibition or activation, ARE or nonsense-
mediated mRNA decay, miRNA-mediated gene silencing, mRNA deadenylaiton, decapping, 5’ to 3’ 
decay, and endocleavage. Second, although many P body components are mRNA degradation factors, 
some P body components are mRNA stabilizers (e.g. eIF4E, HuD, PCBP1, and PCBP2), suggesting that 
some of the mRNAs in P bodies may be protected from degradation, which is consistent with the notion 
that P bodies can be temporary mRNA storage sites. Third, besides the 5’ to 3’ riboexonuclease Xrn1, 
several endonucleases can also be enriched in P bodies; therefore it is possible that decay of some 
mRNAs in P bodies might involve endonucleolytic cleavage. It will be interesting to see how knocking 
down these endonucleases or their activities may impact P body dynamics.  Finally, colocalization of 
protein modification factors, including protein kinases and E3 ubiquitin ligases, with P bodies suggests 
that phosphorylation and ubiquitination may occur in P bodies to directly modulate P body dynamics or 
functions. Conversely, these post-translational modifications may indirectly lead to changes in the 
amount or accessibility of P-body proteins for P-body formation. 
      In this study, I also generate an interactome of P body component.  An analysis of protein-protein 
interactions (PPIs) among human P body protein components shows that at least two thirds of the 
human P body proteins form dense PPI networks (Fig. 4.1), suggesting that collective PPIs among P 
body components contribute to the aggregation of mRNPs during P body formation. Moreover, the 
result indicates that factors involved in the ARE-mediated decay (pink), miRNA-mediated gene 
silencing (blue), and nonsense-mediated decay (cyan) are physically linked. Indeed, the human 
nonsense-mediated decay factor Upf1 also participates in small RNA-mediated gene knockdown (175). 
Similarly, TTP in the ARE-mediated decay pathway binds to Ago2 and Ago4 in the miRNA-mediated 
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gene silencing pathway and is required for mRNA targeting by miR16 (231). Interestingly, although all 
of the above three mRNA decay pathways promote deadenylation, only physical interactions between 
deadenylation factors (yellow) and miRNA-mediated mRNA decay factors (blue) proteins have been 
reported thus far (174). In light of the demonstration that deadenylation is a pre-requisite for P body 
formation and that PABP, not found in P body, is involved in the first phase of deadenylation and is 
removed from mRNA following deadenylation, the PPI analysis provides new insight into the 
mechanism of P body formation.  The following sequential events for P body formation may be 
envisaged.  Following poly(A) shortening via these decay pathways, deadenylases and other 
deadenylation associated factors remain on the mRNPs.  Deadenylation then elicits mRNP remodeling 
that allows other non-deadenylation factors to join the mRNPs.  Remodeled mRNPs aggregate into P 
bodies via multiple PPIs identified among P body components, including the Pan3 deadenylation factor. 
      An analysis of protein-protein interactions (PPIs) between human P body protein components and 
other cellular proteins identified many factors that interact with three or more P body components (Fig 
4.2 and Table 4.3). This in silico approach apparently represents a valid way of identifying factors 
potentially involved in regulating P body dynamics. For instance, some proteins belong to non-P body 
protein families reported to be required for proper P-body formation and/or function (e.g., Hsp90 and 
14-3-3 families) were also included in Table 4.3. Our analysis identified two major cytosolic HSP90 
proteins, HSP90AA1 and HSP90AB1, and inhibition of Hsp90 chaperon activity was reported to affect 
miRNA-mediated gene silencing, siRNA-directed cleavage of target mRNA, and P body formation (229, 
230). We also identified the 14-3-3 protein family (YWHAG, YWHAB, YWHAH, YWHAQ, and 
YWHAZ), which bind to phosphoserine-containing proteins. It is reported that binding of 14-3-3 to 
Edc3 alters P body morphology, inhibits miRNA-mediated gene silencing, and changes Edc3 protein-
protein interactions (206). In addition, the sorting of hMex-3B between P bodies and stress granules is 
regulated by the interaction between hMex-3B and 14-3-3 proteins (224), although this interaction was 
not retrieved using PINA and therefore not included during the analysis. The interactions between 14-3-
3 family proteins and several other reported or predicted P body components (Table 4.3), including 
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LARP1, KLC3, TRIM21 (Ro52), TTP (ZFP36), RCK/p54 (DDX6), suggest that 14-3-3 family of 
proteins play more important roles in regulating P body functions than they were previously thought. It 
is also worth noting that the identification of the interactions between Ago proteins and PABP, which is 
not enriched in mammalian P bodies (21, 71), is consistent with the recent finding that PABP was 
required for miRNA-mediated deadenylation (174). 
      Therefore, PPIs support a hypothesis that the other proteins listed in Table 4.3 may also have P 
body-related functions or even colocalize with P bodies. It will be interesting to test whether or not 
knockdown of these proteins will affect P-body dynamics and whether these proteins themselves 
localize to P bodies as well.    
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      mRNA poly(A) tails, which are essential for both mRNA stability and translation, can be shortened 
in a process termed deadenylation by deadenylases. In this study, I found that the two major mammalian 
deadenylase complexes, Pan3-Pan2 and Ccr4-Caf1, can both localize to mammalian mRNA processing 
bodies (P bodies), which are normally thought to be cytoplasmic sites for mRNA translational inhibition, 
mRNA decapping, and 5’ to 3’ mRNA degradation.  More importantly, my experiments demonstrated 
that deadenylation by the Ccr4-Caf1 complex is a prerequisite for P body formation in mammalian cells.  
      One of the consequences of deadenylation is dissociation of ribosomes from mRNAs. It was known 
that dissociation of ribosomes from mRNAs to render the mRNAs translationally silent is necessary for 
the mRNAs to enter or form P bodies.  However, it was not clear whether the dissociation step alone is 
sufficient or whether other steps are also required.  My work revealed an intriguing finding that even 
when ribosomes are forced to be released from cytoplasmic mRNAs by puromycin treatment, 
deadenylation is still required for P body formation. Given that deadenylation leads to translation 
repression or formation of non-translatable mRNPs, one possible scenario is as follow: when 
deadenylation is inhibited, the poly(A) binding proteins (PABPs) associated with the poly(A) tails 
inhibit mRNAs from forming P bodies by promoting mRNA circularization and preventing the 
displacement of translation activators by specific translation inhibitors that are also found in P bodies. It 
will be interesting to test this hypothesis by analyzing protein components of mRNPs from cells whose 
translation and deadenylation are blocked. 
      Unlike the Ccr4-Caf1 complex, the roles of the Pan3-Pan2 complex in P body formation appear to 
be more complicated. Unlike overexpressing the Caf1 catalytically inactive mutant, overexpression of a 
Pan2 catalytic mutant didn’t inhibit P body formation, suggesting that Pan2 deadenylase activity is not 
essential for P body formation. Consistently, siRNA-mediated knockdown of Pan2 has little effect on P 
bodies.  Interestingly, Pan3 mutants with C-terminal domain truncation, which no longer interact with 
Pan2, still formed many cytoplasmic foci co-localizing with P bodies. The N-terminal domain and 
kinase domain of Pan3, although not required for interaction with Pan2, are thus both important for 
Pan3 to co-localize with P bodies. Moreover, ectopic expression of Pan3 mutants with phosphorylation 
sites mutated at the N-terminal domain, e.g., NP11, results in P body morphology change. Collectively, 
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these observations argue that Pan3 possesses Pan2-independent functions that are essential for P body 
formation. 
      What could be the Pan2-unrelated functions of Pan3 during P body formation? A clue comes from a 
discrepancy between a reported observation and my experimental results. In vitro, purified Pan2 was 
reported to shorten oligo(A) in the absence of Pan3 and PABP. However, I observed that tethered Pan3 
mutants with deletions in the N-terminal domain or kinase domain failed to induce fast deadenylation of 
the reporter mRNA, even though these mutants can still interact with Pan2. One possibility is that in my 
in vivo experiment PABPs associated with the poly(A) tail may block the deadenylase activity of Pan2 
recruited by Pan3 mutants while in the reported in vitro experiment no PABP is present in the reaction. 
The observation that tethered wild-type Pan3, but not Pan3 truncation mutants, induced fast 
deadenylation suggests that Pan3 N-terminal and kinase domains may be required to promote 
dissociation of PABPs from the poly(A) tail. Therefore Pan3 alone might be able to remove PABP from 
the poly(A) tail and allow these poly(A)+ mRNAs to enter P bodies, which might explain why HA-
tagged Pan3 promotes the enrichment of Ccr4-Caf1 and other P body components, but not PABP, in P 
bodies. This hypothesis can be tested by checking the ability of Pan3 or Pan3 mutants (e.g., deficient in 
Pan2 binding) to release PABPs from the poly(A) tail of reporter mRNAs using cytoplasmic lysates 
prepared from cells expressing Pan2 catalytic mutant. 
      Another possible Pan2-independent function of Pan3 in P body formation may involve the Pan3-
Pan3 self-interaction as discovered in yeast (33) and suggested by my preliminary observations in NIH 
3T3 cells. The Pan3-Pan3 self-interaction may promote aggregation of mRNPs during P body formation. 
To further confirm that Pan3 self-interacts within P bodies, the distance between YFP-Pan3 and CFP-
Pan3 in P bodies can be measured using fluorescence resonance energy transfer (FRET). 
      Pan3 N-terminal domain may be phosphorylated to regulate Pan3 localization and functions. Guided 
by two different methods for phosphorylation site prediction, I focused on eleven potential 
phosphorylation sites in Pan3 N-terminal domain. NP11, the Pan3 mutant where the eleven potential 
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phosphorylation sites were replaced by alanine or phenylalaline, induced large and irregularly shaped P 
body formation. On the other hand, PM11, the Pan3 mutant mimicking phosphorylation at the eleven 
sites, no longer colocalizes with P bodies. Instead, it forms nuclear foci. Interestingly, HA-tagged wild-
type Pan3 can also form nuclear foci and be hyper-phosphorylated upon Leptomycin B treatment. Like 
th wild-type Pan3, these two mutants are able to promote reporter mRNA deadenylation and decay 
when tethered to the reporter. It will be interesting to confirm phosphorylation of Pan3 N-terminal 
domain and identify the phosphorylated residues by mass spectrometry analysis of affinity purified HA-
Pan3. Once the phosphorylated sites in Pan3 N-terminal domain are identified, the effects of mutations 
mimicking or inhibiting phosphorylation at those sites on Pan3 localization and functions can then be 
determined.  
      The observation that Pan3(1-353) and Pan3(PM11) formed nuclear foci suggests that Pan3 may play 
a role in the nucleus. In addition, wild-type Pan3 also formed nuclear foci when the cells were treated 
with Leptomycin B, an inhibitor of the nuclear export receptor CRM1. In yeast, Pan3p-Pan2p complex 
trims the poly(A) tails of newly synthesized mRNAs to message-specific length, although it was not 
clear whether this occurs in the nucleus or in the cytoplasm (35). My observations suggest that Pan3-
Pan2 may also trim the poly(A) tails of nascent mRNAs in the nucleus in mammalian cells. To test this 
possibility, we can check if siRNA-mediated knock down of Pan3 or Pan2 results in formation of longer 
poly(A) tails of nuclear mRNA. Since Pan3 nuclear localization may correlate with Pan3 
hyperphosphorylation, it will also be interesting to determine whether Pan3 phosphorylation affects any 
potential nuclear function of Pan3.  
      Aside from focusing on the functions of the two deadenylation complexes in P bodies, I have also 
compiled a list of reported P body protein components and predicted new human P body proteins based 
on sequence homology. The reported and predicted human P body components were categorized 
according to their functions, and their protein-protein interaction networks were visualized and analyzed. 
This effort not only has helped us to better understand the functions of and interactions among human P 
body proteins, but also has yielded some interesting predictions. For instance, my study suggests that 
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cellular proteins able to interact with three or more P body components may also localize to P bodies or 
play a role in P body functions.  In agreement with this prediction, some of the identified proteins have 
already been reported to be important for P body formation or functions. Future experiments along this 
line will be to determine P body-related functions of proteins selected in this study. These experiments 
may reveal novel P body components and post-translational modification pathways that control P body 
dynamics. 
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